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CT TCA. GGA TTA GCT TCA AAA ATA AAT GAT AAT GAC AAT GTA TAT ACT 895 
Pro Ser Gly Leu Ala Ser Lys Ile Asn Asp Asn. Asp Asin Val Tyr Thr 
15 O 15 O 16 O 
TGT. T.T. AAA GCA CAT GAA ACA. TAT ACT ATA TGC TTC GCT AAA GAT ATA 943 
Cys Phe Lys Ala His Glu Thr Tyr Thr Ile Cys Phe Ala Lys Asp Ile 
1.65 17 O 75 
TTC TTT TTA. TAC AGA ACA AGA GAA TAT ATA GGA AAA TTA TTC ATA ATA 99. 
Phe Phie Leu Tyr Arg Thr Arg Glu Tyr Ile Gly Lys Leu Phe Ile Ile 
8 O 85 19 O 
AAA TCA, ATA TTC CCA GAT GAA. ATA TTA. GAT AAT TGG GGA TAT AAA GCT O 39 
lys Se: Ile Phe Pro Asp Glu Ile Leu Asp Asn Trp Gly Tyr Lys Ala 
19 2OO 2O5 
AAA CiT ATA GAT TAT AAT GAA AAA ATA AAT ATA AAT AGA AAC CT CTA O87 
ys i.eu ille Asp Tyr ASn Glu Lys Ile ASn Ile ASn Arg Asn Ser Lieu 
C 215 220 225 
AC AGC AAA AGA GAA CAA. GGA ATG CTT GCT ATA GTA GCA GGA AGT GAT 1135 
Tyr Ser Lys Arg Glu Glin Gly Met Leu Ala Ile Val Ala Gly Ser Asp 
23 O 235 240 
AAT TAT ATA GGG GCT GCT GTT CTA GCT GTA AAT GCT GCT TAT AGA TTG 183 
Asn Tyr Ile Gly Ala Ala Val Lieu Ala Val Asn Ala Ala Tyr Arg Leu 
245 25 O 255 
GGT GTA. GGA TAC ATA AGA TTA. TAT GTA CCT AAA GGC ATA ATA AAA AAT 1231. 
Gly Val Gly Tyr Ile Arg Lieu Tyr Val Pro Lys Gly Ile Ile Lys Asn 
26 O 265 27 O 
ATA AGA GAT GCC ATA ATG CCT TCT ATG CCT GAA ATT GTT ATT ATA GGA 279 
ille Arg Asp Ala Ile Met Pro Ser Met Pro Glu Ile Val Ile Ile Gly 
275 28 O 28S 
GTT GGA GAA GAA AAT CAA AAA TC TTC ACA GAA AAT GAC ATT GAA ATA 327 
Val Gly Glu Glu Asn Glin Lys Phe Phe Thr Glu Asn Asp Ile Glu Ile 
29 O 295 3 O O 3 O 5 
GTA AAT GAT ATI AAT AAA AGC GAT GCT TGT ATA ATA GOGT CT GGT ATA 375 
Val Asn Asp Ile Asn Lys Ser Asp Ala Cys Ile Ile Gly Ser Gly Ile 
31 O 35 32O 
GGC AGA GAT TTG TCT ACA GAA ATT IIT GTA AA ACT ATA ITA AAG CAA 1423 
Gly Arg Asp Leu Ser Thr Glu Ile Phe Val Asn Thr Ile Leu Lys Glin 
3 25 33 O 335 
ATA AAT ATA CCT ACT GTT ATT GAT GCT GAT GCT TTA. TAT TTA ATG TTT 471 
Ile Asn Ile Pro Thr Vall. Ile Asp Ala Asp Ala Leu Tyr Leu Met Phe 
34 O 343 35 O 
FIG. 1B 
FIG 1C 
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GAA AGC ACT CTT AAT GAA CTT AAT AAT AAT TTT ATA ATC ACT CCT CAT 19 
Glu Ser Thr Lieu Asn Glu Lieu. Asn. Asn Asn Phe Ile Ile Thr Pro His 
35 E. 36 O 365 
ATA TAT GAA TTT GAA. AAA CTT ACA CAG ATA AAT CAT ATA GAG GTT TTA S 67 
Ile Tyr Glu Phe Glu Lys Leu Thr Glin Ile Asn His Ilie Glu Val Leu 
37 C. 375 38 O 385 
GAA AAT CCT TAT CAG GCA TTA TTA ATA TAC AGA GAA AAA ACT AAT GCC 1615 
Glu Asr, Pro Tyr Glin Ala Leu Leu Ilie Tyr Arg Glu Lys Thr Asn Ala 
39 O. 395 4 OO 
TCA ATA GTA TTA AAA GAT GCT GTA AGT TTC CTA ATG CAT GAA AAT GAT 1663 
Ser le Val Leu Lys Asp Ala Val Ser Phe Leu Met His Glu Asn Asp 
4 O5 410 45 
ATA TA, ATA AAT TAT AAC CCT AGA GAA TCT ATG GGG AAA GCA GGT ATG 1711 
Ile Tyr Ile Asn Tyr Asn Pro Arg Glu Ser Met Gly Lys Ala Gly Met 
420 425 43 O 
GGT GA GTT TTT GCT GGA TTT ATA GGT GCT TTG CTC GCT AGA AAA CTA 17 S 9 
Gy Asp Val Phe Ala Gly Phe Ilie Gly Ala Leu Lleu Ala Arg Llys Lieu 
43 440 445 
AAT ATA TTA GAT GCT TCA AAA CTA GCA TTG ATA ATA CAG GCT AAA TCT 18 O 7 
Asn Ile Leu Asp Ala Ser Lys Leu Ala Leu Ile Ile Glin Ala Lys Ser 
4 SO 4S5 46 O 4 65 
TTT AAT ATA TTA TCA AAA AAA TTC GGA AAT GAT TAT ATT CAG CCT AAA 855 
Phe Asn. Ile Leu Ser Lys Lys Phe Gly Asn Asp Tyr Ilie Glin Pro Lys 
47 O 475 A 8O 
GAT TTG GCA AAT ATT TCA. TAT AAA ATA CTA AAA GGA TAT AAA TTT GCC 19 O3 
Asp Leu Ala Asn. Ile Ser Tyr Lys Ile Leu Lys Gly Tyr Lys Phe Ala 
485 49 O 4.95 
TAGAGAAGTT TACGACCCTA AACAAAAAGA ATTAGAATTC TACGCTAAAA GAGAGGTAAA 1963 
(CCCCCTGCT CCTAAAAGAG. AGGTA AGCAT ATTTGCTAGA AGATGGTTTA TGTTTTTATA 2023 
CGGAACTTC CTCACATTAG TTGTAATTGG TATGCTTTTA TATAAAAAAG GATTCTTTAA 2O83 
TAATATACCA TTATTTGAAG CTTTAAAGCC TAAAACAGAT GTTATAGTAA AAATTAATAA 243 
TGCTGAATTC GTTAATGATG CAGTAATTAC AACTATAGAA CTCGAAAATT CAAATTATAC 2203 
TAATTCTCAA AGTATAGAAA CACTAAGAAG TTATTTTTCA TTGTACAAAA, ATAGAAAATT 2263 
AATATTTACA GGCAATCGTT CTTTTAATAA TATAAGATTC CCAGTAGGTC AGAGAATAGG 232 3 
ATCAATTT 2332 
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1 
NUCLEOTIDE SEQUENCES FOR 
DETECTION OF SERPULINA 
HYODYSENTERIAE 
This is a divisional of copending application Ser. No. 
08/252,492 filed on Jun. 1, 1994. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH 
The invention described herein was made with the assis 
tance of funds provided by the U.S. Department of 
Agriculture/CSRS, Animal Health Project No. Neb. 14-048, 
Immunobiology of Enteric Diseases of Swine and Cattle; 
U.S. Department of Agriculture, Regional Research Project 
NC-62, Prevention of Enteric Diseases of Swine; U.S. 
Department of Agriculture/NC-IPM, No. Neb. 14-062, Inte 
grated Management Practices for Control of Swine Dysen 
tery and Salmonellosis. The Government has certain rights 
in the invention. 
BACKGROUND OF THE INVENTION 
Swine dysentery is a highly contagious disease of grow 
ing and finishing Swine which has a significant economic 
impact on the United States Swine industry. Although the 
causative agent has been known for nearly 20 years, no 
effective measures, other than medication of animals and 
Sanitation of premises, are available to prevent the occur 
rence of the disease or reduce its Severity once introduced 
into a susceptible herd. Recently published data from Iowa 
State University indicated a projected Statewide cost for 
prevention and control of Swine dysentery of approximately 
S2.4 million per month. Since the Iowa Swine population 
represents one-fourth of the nation's industry, the annual 
losses due to Swine dysentery for the United States may 
represent as much as S115.2 million. Owen, Iowa State J. 
Res., 62:293–311 (1987). 
Serpulina hyOdysenteriae is the primary etiologic agent of 
Swine dysentery. Harris and Lysons, Diseases of Swine, 7th 
ed., Iowa State University Press (Ames, IA), at pp. 599–616 
(1992); and Stanton et al., Int. J. Syst. Bacteriol, 41:50-58 (1991). Nine serotypes of S. hyodysenteriae have been 
recognized Worldwide, with Serotypes 1 and 2 being the 
most prevalent in the United States. Baum and Joens, Infect. 
Immun., 25:792–796 (1979); Mapother and Joens, J. Clin. 
Micro., 22:161-164 (1985); and Liet al., J. Clin. Microbiol., 
29:2794–2797 (1991). The diagnosis of swine dysentery is 
based on herd history, clinical Signs, observation of charac 
teristic intestinal lesions, and isolation of S. hyodysenteriae 
from feces or intestine using Selective agar medium incu 
bated anaerobically for 2 to 4 dayS. Chengappa et al., Report 
of the Committee On Swine Dysentery, American ASSociation 
of Veterinary Laboratory Diagnosticians, Inc. (Columbia, 
Mo.) (1989). Laboratory confirmation of S. hyodysenteriae 
by culture is based upon colony morphology, pattern and 
intensity of hemolysis, and other growth characteristics, all 
of which are very similar for the non-pathogenic Serpulina 
innocenS, a common inhabitant of the colon of Swine. 
Kinyon and Joens, (1979). As a result, a definitive diagnosis 
of Swine dysentery can be very challenging particularly 
when the disease occurs on premises where weakly 
f3-hemolytic intestinal spirochetes (WBHIS) are present in 
the Swine population. 
An important aspect of Swine dysentery is the occurrence 
of prolonged Shedding of S. hyodysenteriae in the feces of 
Some animals following recovery from diarrhea. Songer and 
Harris, Am. J. Vet. Res., 39:913–916 (1978); and Fisher and 
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Olander, Am. J. Vet. Res., 46:450-455 (1981). Asymptom 
atic carrier-Shedder Swine are important reservoirs for main 
tenance of S. hyodysenteriae on infected premises and 
transmission of the organism to uninfected premises. The 
Solution to Swine dysentery prevention lies in being able to 
quickly and accurately identify carrier-Shedder Swine and 
avoid their entry into uninfected herds. However, identifi 
cation of asymptomatic carrier-Shedders of S. 
hyodysenteriae, is difficult due to the detection limits of 
currently available laboratory isolation procedures. 
Direct culture of diagnostic Specimens is the only method 
available for laboratory identification of S. hyodysenteriae. 
However, it is well known that the sensitivity of the direct 
culture method depends upon the number of organisms 
present in the Sample, which in turn depends on the Stage of 
infection of the animal at the time of collection. Kunkle and 
Kinyon reported that the numbers of S. hyodysenteriae in 
porcine colonic contents at the onset of Swine dysentery 
ranged between 2x10° and 2x10' CFU/g when cultured 
using the selective BJ medium. Kunkle et al., J. Clin. 
Microbiol., 26:2357–2360 (1988). In contrast, subclinically 
affected animals may shed recoverable numbers of Spiro 
chetes only sporadically and in much lower numbers than 
animals with clinical Swine dysentery often resulting in false 
negative culture results. Field cases of Swine dysentery also 
may contain drug residues that adversely affect recovery of 
viable S. hyodysenteriae by culture. 
Identification of S. hyodysenteriae by culture is highly 
Subjective and can lead to false results, particularly when 
results of cultures are interpreted by inexperienced labora 
tory workers. For this reason, Several biochemical tests have 
been proposed for rapid differentiation of enteropathogenic 
and non-pathogenic intestinal Spirochetes of Swine. Achacha 
et al., J. Vet. Diag. Invest., 3:211-214 (1991); Belanger et al., 
J. Clin. Microbiol., 29:1727–1729 (1991); Hunter et al., Vet. 
Rec., 104:383–384 (1979); and Smith et al., Vet. Microbiol., 
24:29-41 (1990). Although these biochemical characteris 
tics are highly conserved among field isolates of S. 
hyodysenteriae, WBHIS have been shown to yield highly 
variable results making a conclusive identification of S. 
hyOdysenteriae based on biochemical tests alone practically 
impossible. Achacha et al, cited Supra; Belanger et al., cited 
supra; Burrows et al., Vet. Rec., 108:187-189 (1981); Kin 
yon et al., Infect. Immun., 15:638-646 (1977); Lymbery et 
al., Vet. Microbiol., 22:89-99 (1990); Picard et al., Can. J. 
Microbiol., 26:985–991 (1980); Ramanathan et al., Vet. 
Microbiol, 37:53-64 (1993); and Torp and Thorensen, Proc. 
12th Congr. Int. Pig Vet. Soc., The Hague, The Netherlands, 
at page 270. (1992). In addition, the biochemical tests 
require growth of the organism for 2 to 4 dayS. 
Other methods of differentiating S. hyodysenteriae from 
WBHIS include growth inhibition by discs soaked in anti 
serum (Lemcke and Burrows, Vet. Rec., 104:548–551 (1979)) and rapid slide agglutination (Burrows and Lemcke, 
Vet. Rec., 108:187-189 (1981)). In addition to problems of 
non-specific clumping of Spirochetes in the Saline control in 
the slide agglutination test, these tests require large numbers 
of pure culture of Spirochetes which can take up to 3 weeks 
to grow. Lysons, Vet. Rec., 129:314-315 (1991). Although 
pre-absorption of reference polyclonal antisera with WBHIS 
increases the Specificity of the Serological tests, occasional 
S. hyodysenteriae isolates continue to be falsely classified as 
non-pathogenic in these tests. An alternative method using 
microscopic agglutination under phase contrast or dark field 
microScopy was recently proposed. However, Some isolates 
of S. hyodysenteriae gave weaker reactions in that assay than 
with the Slide agglutination test (LySons, cited Supra). 
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Mouse monoclonal antibodies capable of differentiating 
S. hyodysenteriae from porcine WBHIS have also been 
proposed as potential diagnostic reagents. Sellwood et al., 
Proc. 12th Congr: Int. Pig Vet. Soc., The Hague, The 
Netherlands, at page 264 (1992); and Thomas and Sellwood, 
J. Med. Microbiol, 37:214–220 (1992). However, other 
Studies, indicate that Spirochetes other than S. hyodysente 
riae can express antigenic determinants recognized by these 
reagents and cause false positive results. Taylor et al., PrOC. 
12th Conqr. Int. Pig Vet. Soc., The Hague, The Netherlands, 
at page 280 (1992). The fact that no Serological reagents are 
available commercially also limits the applicability of Sero 
logical techniques to routine diagnosis of Swine dysentery. 
Certain genes encoding S. hyodysenteriae antigens and 
capable of eliciting protection against infection in mice have 
been cloned and expressed in Escherichia coli using a phage 
expression System. Boyden et al., Infect. Immun., 
57:3808-3815 (1989). However, none of these reagents 
have been examined for potential application as diagnostic 
tools. One of the most recent diagnostic applications of 
recombinant DNA technology to Swine dysentery control 
used oligodeoxynucleotide probes to 16S rRNA of S. hyo 
dysenteriae. Jensen et al., J. Clin. Microbiol., 28:2717-2721 
(1990). However, the sensitivity of this probe method for 
detection of Spirochetes in feces was equivalent to routine 
bacteriological culture (10 organisms/g of feces), and fur 
ther studies question the specificity of the 16S rRNA probe 
to S. hyodysenteriae (Torp and Thoresen, cited Supra). Dot 
blot hybridization with whole-chromosomal probes and 
DNA probes for identification of S. hyodysenteriae have 
been reported. Combs and Hampson, Res. Vet. Sci., 
50:286-289 (1991); Sotiropoulos et al., J. Clin. Microbiol., 
31:1746-1752 (1993); and Sotiropoulos et al., J. Clin. 
Microbiol, 32:1397-1401 (1994). Although the sensitivity 
of the whole-chromosomal probes was not reported, colony 
dot blot hybridization with DNA probes was shown to be 
only slightly better than culture (10' organisms/g of feces). 
These tests are labor intensive, require Specialized 
equipment, and have turn-around times that are incompat 
ible with routine laboratory diagnosis. 
A Solution to prevention of disease caused by S. hyodys 
enteriae lies in being able to quickly and accurately identify 
carrier-Shedder animals and avoid their entry into uninfected 
herds. Therefore, there is a need to develop a method and 
reagents for detecting S. hyodysenteriae in low numbers 
Specifically, rapidly and directly from diagnostic and envi 
ronmental Samples. There is also a need to develop a 
Sensitive and Specific method for rapid detection of S. 
hyOdysenteriae in a biological Sample to diagnose and 
monitor infection in acutely- or Subclinically-infected ani 
mals before, during and after treatment and in their envi 
ronment. There is also a need to develop a method for rapid 
detection of S. hyodysenteriae for monitoring disinfection of 
the environment in contact with infected animals. 
SUMMARY OF THE INVENTION 
These and other objects are achieved by the present 
invention which is directed to a method for detecting the 
presence of at least one Serotype of Serpulina hyOdysente 
riae in a biological Sample, an oligonucleotide primer, and 
a S. hyodysenteriae-Specific oligonucleotide probe useful in 
that method, and an article of manufacture (i.e., kit) con 
taining the primers and/or probe. Also provided are an about 
2.3-kb DNA fragment derived from chromosomal DNA of S. 
hyodysenteriae B204 serotype 2 that encodes for an about 56 
kDa polypeptide, a recombinant expression vector contain 
ing the DNA fragment, the about 56 kDa polypeptide and a 
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monoclonal antibody reactive with the peptide. The inven 
tion also provides for a method of immunizing animals and 
vaccine preparations for protecting animals against disease 
caused by S. hyodysenteriae. The methods and compositions 
of the invention are useful to identify at least one Serotype 
of S. hyodysenteriae, to diagnose S. hyodysenteriae 
infection, to detect carrier-Shedder animals, to monitor effi 
cacy of treatment for disease caused by S. hyodysenteriae, to 
monitor disinfection of fomites, and to protect animals from 
infection with S. hyodysenteriae. 
According to the invention, a biological Sample of an 
animal Such as feces, intestinal contents, mucosal Scrapings, 
rectal Swabs, and environmental Samples among others, is 
tested for the presence of at least one Serotype of S. 
hyOdysenteriae by measuring the presence or absence of 
DNA amplification products from a primer that hybridizes to 
a 2.3 kb HindIII restriction fragment of S. hyodysenteriae 
B204 serotype 2. The 2.3 kb HindIII restriction fragment 
was obtained from a partial digest with HindIII and prefer 
ably has a nucleotide sequence as shown in FIG. 1 (SEQ ID 
NO:1). The DNA amplification products specific for S. 
hyodysenteriae can be detected by (a) extracting DNA from 
a biological Sample; (b) amplifying a target Sequence of the 
extracted DNA to provide DNA amplification products 
carrying a selected target DNA sequence; and (c) detecting 
the presence of S. hyodysenteriae by detecting the presence 
of the DNA amplification products. Preferably, the amplifi 
cation of the DNA sequence is by polymerase chain reaction 
(PCR) by amplifying the gene sequence with DNA poly 
merase and at least one oligonucleotide primer. The primers 
preferably have a Sequence of positive-Sense 
5'-GGTACAGGCGGAAACAGACCTT (SEQ ID NO:3), or 
negative-sense 5'-TCCTATTCTCTGACCTACTG (SEQ ID 
NO:4), or complements thereof or mixtures thereof. 
The amplification products can be detected, for example, 
by dot blot or Southern blot analysis including by reacting 
the DNA amplification products with a labeled oligonucle 
otide probe that can hybridize to the about 2.3 kb HindIII 
DNA fragment of S. hyodysenteriae B204 serotype 2 shown 
in FIG.1. Prior to detection, the DNA amplification products 
can optionally be separated by electrophoresis. 
Alternatively, the PCR products can be detected by immo 
bilization to a bead or a multiwell plate by a probe or primer 
labeled with biotin, followed by hybridization with a detect 
ably labeled probe. The oligonucleotide probe preferably 
hybridizes to all or a portion of a 2.3 kb HindIII DNA 
fragment of S. hyodysenteriae B204 serotype 2 having the 
nucleotide sequence shown in FIG. 1 (SEQ ID NO:1). The 
detection of amplified products preferably allows for the 
detection of all serotypes of S. hyodysenteriae at low levels 
of bacteria in the sample (i.e., about 1 to 10 microorganisms/ 
0.1 gm sample). 
The invention provides an isolated HindIII DNA fragment 
of about 2.3-kb that is derived from a partial digest of 
chromosomal DNA of S. hyodysenteriae B204 serotype 2 
with HindIII, which encodes for an about 56 kDa polypep 
tide. The DNA fragment preferably has the nucleotide 
sequence shown in FIG. 1 (SEQ ID NO:1). 
The DNA restriction fragment may be incorporated into 
an expression vector. The expression vectors include the 
restriction fragment operably linked to transcriptional and 
translational control regions in the vector. The expression 
vectors are useful to form transformed cells. The trans 
formed cells can be used to Screen monoclonal antibodies 
Specific for S. hyodysenteriae to produce a 56 kDa polypep 
tide of S. hyodysenteriae, to prepare mutant Sequences of the 
2.3 kb HindIII restriction fragments, and as an intermediate 
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to prepare the 2.3 kb HindIII restriction fragment for DNA 
sequencing. A puC18 plasmid carrying the 2.3 kb HindIII 
restriction fragment from S. hyodysenteriae B204 and des 
ignated pRED3C6, deposited with the American Type Cul 
ture Collection, Rockville, Md., has been given Accession 
No. 75826. 
Also provided are oligonucleotide primers that hybridize 
to all or a portion of a DNA sequence of the 2.3 kb HindIII 
fragment of S. hyodysenteriae B204 serotype 2 (SEQ ID 
NO:1). The DNA sequence of a oligonucleotide primer is 
preferably positive - Sense 
5'-GGTACAGGCGGAAACAGACCTT (SEQ ID NO:3) 
and negative-sense 5'-TCCTATTCTCTGACCTACTG 
(SEQ ID NO:4), or complements thereof or mixtures 
thereof. The primers can be complementary to the 3' or 5' 
end of the target Sequences. The primers can also have 
mismatches with the target Sequence or be degenerate. 
The target DNA sequence is also useful in providing an 
oligonucleotide probe for detecting a target Sequence of at 
least one Serotype of S. hyodysenteriae. The probe is pref 
erably hybridizable with a DNA sequence located on the 2.3 
kb HindIII fragment of the chromosomal DNA of S. 
hyodysenteriae, preferably a 1.55 kb DNA sequence within 
the 2.3 kb fragment. The DNA sequence of the oligonucle 
otide probe is preferably hybridizable to all or a portion of 
the 2.3 kb HindIII fragment of S. hyodysenteriae B204, as 
shown in FIG. 1, and can distinguish S. hyodysenteriae from 
other microorganisms and cells in a biological Sample. 
The about 56 kDa polypeptide encoded by the about 2.3 
kb DNA fragment is useful in eliciting antibodies that are 
specifically reactive with S. hyodysenteriae. The 56 kDa 
polypeptide and nucleotide Sequence encoding the polypep 
tide may also be useful in a vaccine preparation to provide 
a protective effect for an infection caused by S. hyodysen 
teriae. The invention further provides an in vitro assay for 
detecting S. hyodysenteriae-specific antibodies in a Sample. 
In that method, a Sample to be tested is contacted with a 
composition containing the about 56 kDa polypeptide, 
which is preferably labelled, to form a conjugate which is 
then detected. 
An article of manufacture (i.e., kit) is also provided for 
use in the detection of at least one Serotype of S. hyodyS 
enteriae in a biological Sample. The kit is composed of one 
or more reagents contained within a packaging material, the 
reagents useful for detection of the Spirochete including at 
least one oligonucleotide primer that hybridizes to a DNA 
sequence of the 2.3 kb fragment of S. hyodysenteriae B204 
as shown in FIG. 1, and/or an oligonucleotide probe which 
is hybridizable to all or a portion of a DNA gene Sequence 
included in the 2.3 kb gene fragment, preferably an about 
1.55 kb gene fragment. The kit may optionally include 
instruction means with information regarding the use of the 
reagent and/or other component of the kit Such as how to 
conduct an assay, and the like. The instruction means may be 
a label or tag attached to the packaging, a printed package 
insert, and the like. Two or more reagents and/or other 
components may be combined together to form the kit, 
preferably packaged together within containing means Such 
as a box or plastic bag, and the like. 
The kits and methods of the invention can be used to 
identify at least one Serotype of S. hyodysenteriae to diag 
nose S. hyodysenteriae infection, detect carrier-Shedder 
animals, monitor the efficacy of treatment for diseases 
caused by S. hyodysenteriae, or monitor disinfection of the 
environment. A method for monitoring the efficacy of treat 
ment is useful to ensure that Subclinically infected or carrier 
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shedder animals are not formed. The method involves moni 
toring the presence of S. hyodysenteriae throughout the 
course of treatment of the animal. The presence of S. 
hyOdysenteriae in a biological Sample from the treated 
animal is detected by detecting DNA amplification products 
of a target Sequence of S. hyodysenteriae, wherein the target 
sequence is a 2.3 kb HindIII restriction fragment of S. 
hyOdysenteriae. 
The invention also provides for vaccines and methods of 
immunizing an animal to produce a protective immune 
response against S. hyodysenteriae infection. The vaccines 
include an amount of a 56 kDa polypeptide encoded on a 2.3 
kb HindIII restriction fragment of S. hyodysenteriae B204 
effective to induce a protective response to S. hyodysenteriae 
infection. The vaccine preparations are in admixture with a 
physiologically acceptable carrier and can be administered 
to animals using Standard methods. The vaccines and meth 
ods of the invention are useful to prevent the adverse effects 
of disease caused by S. hyodysenteriae. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows the nucleotide sequence of the recombinant 
2.3-kb HindIII DNA fragment from Serpulina hyodysente 
riae (SEQ ID NO: 1) which indicates a single open reading 
frame encoding a protein with a predicted molecular weight 
of approximately 56 kDa (SEQ ID NO:2). 
FIG. 2 is an image of a Southern blot hybridization using 
C-'PdCTP labelled 2.3 kb fragment of clone pRED3C6 to 
purified chromosomal DNA. Purified chromosomal DNA 
was digested with HindIII, electrophoresed on a 0.8% aga 
rose gel, and transferred to a nylon membrane. Lanes 1 to 8, 
Serpulina hyodysenteriae isolate B78, B234, B204, B169, 
Al, B8044, B6933, and AcK300/8, respectively; lanes 9 to 
12, WBHIS B256, B359, B1555a, and 4/71, respectively; 
lane 13, Treponema Succinifaciens. 
FIG. 3 is an image of an ethidium bromide Stained agarose 
gel and Southern blot hybridization of PCR using purified 
chromosomal DNA obtained from reference isolates of S. 
hyodysenteriae serotypes 1 through 9. The amplified prod 
ucts were electrophoresed on a 0.8% agarose gel and Stained 
with ethidium bromide. The insert at the bottom of the 
photograph shows hybridization of transferred DNA from 
the same gel with an internal S. hyodysenteriae-specific 
oligonucleotide probe 5'-end labelled with Y- PATP. 
Lanes: 1, molecular weight standard (1-kb DNA ladder; 
GIBCO-BRL); 2, B78; 3, B204; 4, B169; 5, A1; 6, B8044; 
7, B6933; 8, AcK300/8; 9, FM-88-90; 10, FMV 89-3323. 
FIG. 4 is an image of an ethidium bromide Stained agarose 
gel (panel A) and Southern blot hybridization (panel B) of 
PCR using purified DNA obtained from porcine feces inocu 
lated with serial ten fold dilutions of Serpulina hyodysen 
teriae isolate B204 cells. FIG. 4A shows the amplified 
products electrophoresed on a 0.8% agarose gel and Stained 
with ethidium bromide. FIG. 4B shows hybridization of 
transferred DNA from the same gel with an internal S. 
hyodysenteriae-Specific oligonucleotide probe 5'-end 
labelled with Y--PATP. Lanes: 1, molecular weight stan 
dard (1-kb DNA ladder; GIBCO-BRL); lanes 2 to 9, feces 
containing 10, 10, 10, 10, 10", 10, 10, 10° S. 
hyOdysenteriae cells/0.1 g, respectively. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The invention provides for methods, kits and composi 
tions useful for diagnosis and monitoring of infection of 
animals with at least one Serotype of S. hyodysenteriae. The 
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compositions include probes and primers that can hybridize 
to a target Sequence of at least one Serotype of S. hyOdyS 
enteriae. The probes and primers can preferably hybridize to 
all Serotypes of S. hyodysenteriae and not other closely 
related microorganisms. The target Sequence is preferably 
about a 2.3 kb fragment of S. hyodysenteriae chromosomal 
DNA having the nucleotide sequence shown in FIG. 1 (SEQ 
ID NO:1). The primers and probes can be used in methods 
and kits for detecting S. hyodysenteriae in a biological 
Sample, preferably by detecting amplification products using 
primers that hybridize to the target Sequence. 
The invention also provides a 56 kDa polypeptide 
encoded by a 2.3 kb HindIII restriction fragment of S. 
hyodysenteriae B204, as shown in FIG. 1. The polypeptide 
and nucleotide Sequences are useful to elicit antibodies and 
in vaccine formulations. The vaccine can be administered to 
animals to induce a protective immune response against 
infection with S. hyodysenteriae. 
1. Primers and Probes that Hybridize to a Target Sequence 
of S. hyodysenteriae 
Primers and probes of the invention are useful for iden 
tification of at least one Serotype of S. hyodysenteriae in a 
biological Sample. The primers and probes are preferably 
those that hybridize to a target Sequence of about a 2.3 kb 
fragment of S. hyodysenteriae B204 having the nucleotide 
sequence of FIG. 1 (SEQ ID NO:1). Hybridization of the 
primerS and/or probes to the target Sequence preferably can 
provide for identification of all serotypes of S. hyodysente 
riae and distinguish S. hyodysenteriae from other cells and 
closely related microorganisms. Primers can be useful in a 
diagnostic assay to identify at least one Serotype of S. 
hyOdysenteriae and to distinguish S. hyodysenteriae from at 
least one other microorganism, and to form probes or to form 
deletion mutants of the target Sequence. Probes are useful to 
identify at least one Serotype of S. hyodysenteriae and/or to 
distinguish S. hyodysenteriae from at least one other 
microorganism, to identify amplification products of a target 
Sequence, and to identify other target Sequences. 
Primers and probes in accord with the invention are 
Selected So that they can Specifically identify at least one 
Serotype of S. hyodysenteriae, preferably all Serotypes. 
Those primerS or probes that can Specifically identify S. 
hyOdysenteriae are those that hybridize to a target Sequence 
preferably found in all Serotypes and not found in other 
closely related microorganisms. One Such target Sequence 
identified in all serotypes of S. hyodysenteriae is about a 2.3 
kb fragment of S. hyodysenteriae B204 shown in FIG.1. The 
2.3 kb fragment was obtained by partial digestion of chro 
mosomal DNA with HindIII. 
The target Sequence Specific for S. hyodysenteriae can be 
identified from a DNA or cDNA library of S. hyodysenteriae 
chromosomal DNA or mRNA, respectively. A DNA or 
cDNA library can be generated by Standard methods using 
a restriction enzyme such as HindIII. Suitable host cells such 
as E. coli DH5C. and the like are transformed with the 
library. Transformed cells can be screened by a variety of 
Standard methods including by reactivity with antibodies 
that react with antigens of S. hyodysenteriae. 
Once a clone that reacts with the antibodies that react with 
antigens of S. hyodysenteriae is identified, it can be ampli 
fied and Sequenced. An example of a target Sequence is a 2.3 
kb fragment having a nucleotide Sequence shown in FIG. 1 
(SEQ ID NO 1). This sequence encodes a 56 kDa polypep 
tide having a predicted amino acid Sequence as shown in 
FIG. 1 (SEQ ID NO:2). Transformed cells including this 
target Sequence were immunoreactive with monoclonal anti 
body 10G6/G10 (available from Dr. Duhamel at University 
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of Nebraska, Lincoln, Nebr) raised against cell-free Super 
natant antigens of S. hyodysenteriae B204. 
A target Sequence can be isolated and labeled with a 
detectable label Such as a radioactive nucleotide. The target 
Sequence can also serve as a probe and can be Screened for 
hybridization to all serotypes of S. hyodysenteriae and for 
lack of hybridization to other microorganisms Such as S. 
innocens, WBHIS strains, Treponema spp., E. coli, Salmo 
nella spp., Campylobacter spp., Bacteriodis vulgatus, Spi 
rocheta aurantia, Borrellia burgdorferi, and Leptospiraceae. 
Hybridization conditions are preferably low Stringency con 
ditions. The target Sequence, as well as probes and primers 
derived from the target Sequence, can be used to confirm the 
identity of a pure culture of S. hyodysenteriae isolated by 
conventional microbiological methods or isolated by immu 
noaffinity methods, to distinguish at least one Serotype of S. 
hyOdysenteriae from other cells in a mixed biological 
Sample including other microorganisms and eukaryotic 
cells. Preferably the probe derived from a target Sequence 
can hybridize to all Serotypes of S. hyodysenteriae and not 
to closely related S. innocens, WBHIS strains, Treponema 
spp. Once a target Sequence is identified, Screened for 
Specificity for at least one Serotype to S. hyodysenteriae and 
Sequenced, it can be used to design primerS and/or probes. 
Once the Sequence of a target Sequence from one Serotype 
of S. hyodysenteriae is known, primers and probes that 
hybridize to the known target Sequence can be used to 
identify other closely related target Sequence from other 
Serotypes that will hybridize to the same primers and/or 
probes. For example, other target Sequences from other 
serotypes of S. hyodysenteriae can have some DNA 
sequence differences from the 2.3 kb HindIII restriction 
fragment from B204 serotype 2, shown in FIG. 1, and still 
be able to hybridize to primers and probes that hybridize to 
the 2.3 kb sequence as shown in FIG. 1 under low, medium 
or high Stringency conditions. These other target Sequences, 
once identified, can be sequenced and used to provide a 
template for design of primers and/or probes. Once Selected, 
these target Sequences are further preferably Screened for the 
ability to hybridize to Sequences in all Serotypes of S. 
hyOdysenteriae and not to related microorganisms. Such as S. 
innocens, Treponema spp., and WBHIS spp., and the like. 
At least one primer is designed to be useful to amplify the 
target DNA sequence preferably using Standard or hot start 
polymerase chain reaction. A primer can preferably be about 
16 to 30 nucleotides long and more preferably about 20 to 
21 nucleotides long. Primers can hybridize to Sequences 
flanking the desired target Sequence which is preferably all 
or a portion of a 2.3 kb fragment of S. hyodysenteriae B204 
having the nucleotide sequence shown in FIG. 1. Primers 
can hybridize to sequences at the 5' and/or 3' ends of the 
target sequence. Primers can hybridize to the DNA strand 
with the coding Sequence of a target Sequence and are 
designated sense primers. Primers can hybridize to the DNA 
Strand that is the complement of the coding Sequence of a 
target Sequence and are designated anti-Sense primerS. Prim 
ers that hybridize to each strand of DNA in the same location 
or to one another are known as complements of one another. 
Primers can be designed to hybridize to a mRNA sequence 
complementary to a target DNA sequence and are useful in 
reverse transcriptase PCR. 
Hybridization conditions utilized are those preferred for 
polymerase chain reaction modified as required for the 
degree of Sequence complementarity of the primers to the 
target Sequence. Hybridization conditions for a primer of 
about 16 to 30 nucleotides long having no mismatches with 
the target Sequence are those described by Elders et al., J. 
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Clin. Micro, 32:1497 (1994). Briefly, a PCR mixture includ 
ing 4 mM MgCl, 0.2 mM dNTPs and a DNA polymerase 
were mixed with the DNA extracted from the biological 
sample. Initial denaturing is at 95 C. for 60 seconds 
followed by 30 cycles (65° C. for 60 seconds and 72° C. for 
120 seconds). The conditions selected are those described 
for GenAmp 480 (Perkin-Elmer, Norwalk, Conn.). 
Hybridization conditions for a primer having about 16 to 
30 nucleotides and about up to 30% mismatch are modified 
as described in Maniatis, Molecular Cloning. A Laboratory 
Manual, Cold Spring Harbor, N.Y. (1989). The melting 
temperature (T) for hybridization is decreased about 1 to 
1.5 C. for each 1% of mismatch. Primers less than 20 
nucleotides preferably only have about one to three mis 
matches with the target Sequence located at either the 5' or 
3' end of the primer. PCR methods using mismatched 
primerS or degenerate primers have been described. 
Primers can be designed as overlapping Sequences or a 
nested Set as long as all or a portion of the target Sequence 
can be amplified. Primers can include at least about 16 
nucleotides Starting from the flanking Sequence immediately 
adjacent to the 5' end of the target Sequence and overlapping 
primers can be designed to move from the 5' end to the 3' end 
of the target Sequence as shown below: 
target sequence 
Likewise, primers can be designed to include about 16 
nucleotides Starting from the flanking Sequence immediately 
adjacent to the 3' end and then overlapping the Sequence 
until the 5' end of the target Sequence. These primers can 
vary in size from about 16 to 100 nucleotides. A primer that 
hybridizes to a flanking region preferably hybridizes to 
about 16 to 30 nucleotides immediately upstream or down 
Stream from the target Sequence. These overlapping primers 
provide for amplification of all or a portion of the target 
Sequence preferably at least about 16 nucleotides long and 
more preferably about 20 to 2,300 nucleotides long. 
Primers can preferably hybridize under standard condi 
tions for polymerase chain reaction to a portion of the target 
nucleotide Sequence or to the flanking Sequences immedi 
ately adjacent to the target Sequence and provide for ampli 
fication of all or a portion of a target Sequence including 
preferably a 2.3 kb HindIII partial digest restriction fragment 
of S. hyodysenteriae B204. Primers preferably hybridize to 
the target Sequence with no mismatches. However, primers 
can have additional nucleotide Sequence at the 5' or 3' ends, 
as for example, to provide restriction enzyme recognition 
Sequences. Restriction enzyme recognition Sequences are 
known to those with Skill in the art and can provide an 
amplified product with restriction endonuclease recognition 
Sequence at one or both ends of the amplified products. 
Other Sequences can be added at one or both ends of the 
primers to act as markers of the amplified products as, for 
example, a universal primer Sequence. 
Primers can also be designed that are not perfectly 
complementary and Still can hybridize to a portion of the 
target Sequence or flanking Sequence and thereby provide for 
amplification of all or a portion of a target Sequence. Primers 
of about 20 nucleotides or less preferably have about one to 
three mismatches located at the 5' and/or 3' ends. Primers of 
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about 20 to 30 nucleotides have up to 30% mismatches and 
can Still hybridize to a target Sequence. Hybridization con 
ditions for primers with mismatch can be determined by the 
method described in Maniatis at pages 11.55 to 11.57 which 
is hereby incorporated by reference or by reference to 
known methods. The ability of the primer to hybridize to the 
2.3 kb HindIII sequence of FIG. 1 under varying conditions 
can be determined using this method. Because a target 
Sequence is known, the effect of mismatches can be deter 
mined by methods known to those of skill in the art. 
Hybridization conditions for polymerase chain reaction 
using degenerate or mismatched primers are known to those 
of skill in the art. 
In a preferred version, primer pairs are designed to flank 
a desired portion of the target Sequence. A primer pair has a 
first primer that hybridizes to a sense strand at the 5' end of 
the target Sequence and a Second primer that hybridizes to 
the anti-Sense Strand at the 3' end of the target Sequence. 
Examples of the preferred primers include Sense 
5'-GGTACAGGCGGAAACAGACCTT (SEQ ID NO:3); 
anti-sense 5'-TCCTATTCTCTGACCTACTG (SEQ ID 
NO:4). The preferred primers can hybridize to and amplify 
all or a portion of a 2.3 kb HindIII restriction fragment 
Sequence of S. hyodysenteriae B204 Serotype 2, as shown in 
FIG. 1. 
Once the primers are designed as described above, the 
primers can be prepared by automated DNA Synthesis in 
accord with Standard methods. 
Once the target Sequence has been identified, the target 
Sequence can Serve as a probe or can be used to design other 
probes. A probe can hybridize to all or a portion of a target 
Sequence, preferably under all Stringency conditions. The 
preferred probes hybridize to all or a portion of a 2.3 kb 
HindIII partial digest restriction fragment of S. hyodysente 
riae B204 as shown in FIG. 1. The probes are useful to 
detect amplified products of the target Sequence and to detect 
and identify at least one Serotype of S. hyodysenteriae. 
A probe can have about 16 to about 2300 nucleotides, 
more preferably about 25 to 100 nucleotides. A probe can 
hybridize to all or a portion of a target Sequence. If a probe 
is designed to detect amplified products of the target 
Sequence, it is preferably designed not to hybridize to the 
Sequence of primers used for amplification. A probe 
designed to detect amplification products can preferably 
hybridize to Sequences between the primer Sequences. A 
probe can hybridize to the DNA strand with coding sequence 
and is designated a Sense probe. A probe can hybridize to the 
DNA strand that is complementary to the strand with the 
coding Sequence and is designated an anti-Sense probe. A 
probe can be designed to hybridize to mRNA complemen 
tary to the target Sequence. 
Hybridization conditions for forming hybrids for a probe 
of about 16 to 100 nucleotides or more without any mis 
matches are preferably those described in Flores et al., J. of 
Vir, 64:4021 (1990). Briefly, immobilized target sequences 
are incubated at 53 C. for 16 to 32 hours in 4xSSC 
(1xSSC=0.15M NaCl plus 0.015M sodium citrate), 0.02% 
Sodium dodecyl sulfate, 50% formamide, 50 mM potassium 
phosphate buffer, 10% Dextran sulfate, 0.02% Ficoll 
(Pharmacia, Inc., Piscataway, N.J.), 0.02% bovine serum 
albumin, 0.02% polyvinylpyrrolidone, 20 tug sheared salmon 
DNA per ml, and the probe. Prehybridizations are carried 
out in the same buffer minus dextran Sulfate. After 
incubation, the hybrids are washed four times for 5 minutes 
at room temperature with 0.1% sodium dodecyl sulfate in 
2.5xSSC, and then twice for 15 minutes at 53 C. with 
0.05% sodium dodecyl sulfate in 1.25xSSC. These condi 
tions can be modified, if necessary, depending on the method 
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of detection employed, Such as dot blot hybridization, 
Southern blot hybridization, or multiwell solution hybrid 
ization. Modification of hybridization conditions depending 
on the method employed are known. 
A probe of the invention can be perfectly complementary 
to the target Sequence or can have Some mismatches with the 
target Sequence. A probe of about 16 to 20 nucleotides 
preferably has about 1 to 3 mismatches localized near the 5' 
or 3' ends of the probe (i.e., within 5 base pairs of either end). 
Probes of about 20 to 2300 nucleotides can have up to about 
30% mismatches and still hybridize to the target sequence. 
Mismatched probes can Still hybridize to the target Sequence 
if conditions of hybridization are modified to account for the 
mismatch, as, for example, by decreasing melting tempera 
ture by about 1.0 to 1.5 C. for every 1% of mismatch. 
Because a target DNA sequence has been cloned and 
identified, the effect of mismatches in the probe on T. (melting temperature) can be determined using a standard 
method such as described by Maniatis at pages 11.47 to 
11.57, which is hereby incorporated by reference. 
Probes can also be detectably labeled using a variety of 
standard methods. The probes can be detectably labeled by 
incorporating one or more labeled nucleotides into the 
probe. Nucleotides can be labeled with biotin, with a 
radiolabel, or with a fluorescent moiety or luminescent 
moiety and the like. 
A preferred probe of the invention can hybridize to all or 
a portion of a 2.3 kb HindIII restriction fragment of S. 
hyodysenteriae B204 (SEQ ID NO:l) or to amplification 
products of a 2.3 kb HindIII restriction fragment from 
Serotype B204 and other Serotypes. A preferred probe has a 
Sequence as follows: 
Sense-5'-TAGGGGCTGCTGTTCTAGCTGTAAATGC 
(SEQ ID NO:5) 
and can hybridize to about a 1.5 kb amplification product of 
S. hyodysenteriae B204 and other serotypes and to the 2.3 kb 
HindIII fragment under low Stringency conditions. 
Once designed, a probe can be prepared by automated 
DNA Synthesis or by polymerase chain reaction using appro 
priate primers. The probe can also be prepared by digesting 
the 2.3 kb insert in pRED3C6 with any one or more of the 
restriction enzymes shown in Table I. 
A probe according to the invention can be used in a 
method for identifying at least one Serotype of S. hyOdyS 
enteriae or distinguishing S. hyodysenteriae from at least 
one other microorganism. The probes are used in methods 
Such as restriction enzyme, PCR amplification, Slot blot, dot 
blot, and Southern blot analysis of DNA taken from bio 
logical Samples Suspected of containing at least one Serotype 
of S. hyodysenteriae. The steps of the method include 
isolating DNA from a biological Sample Suspected of con 
taining at least one Serotype of S. hyodysenteriae, digesting 
the extracted DNA with at least one restriction enzyme, and 
detecting any Sequence Specific to S. hyodysenteriae by 
hybridization to a probe Specific for at least one Serotype of 
S. hyodysenteriae chromosomal DNA. 
The extraction of DNA from a biological sample can be 
accomplished by Standard methods. Elder et al., cited Supra. 
Biological Samples can include pure cultures of bacteria 
isolated by Standard microbiological methods or a biological 
Sample Suspected of having at least one Serotype of S. 
hyOdysenteriae as well as other microorganisms. Examples 
of biological Samples include feces, intestinal contents, 
intestinal mucosal Scrapings, fecal Swabs and the like. 
Environmental Samples are also biological Samples Such as 
manure, manure-contaminated Soil, fomites, pits, lagoon 
water, or effluent from a premises Suspected of containing S. 
hyOdysenteriae. 
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The extract is then digested with at least one restriction 
enzyme. The choice of restriction enzyme is based upon the 
Sequence of the DNA target Sequence Specific for S. hyod 
ySenteriae and the recognition Sequence of the restriction 
enzyme. Recognition Sequences for restriction enzymes are 
known to those of skill in the art. If all or a portion of the 
DNA sequence of the target Sequence for S. hyodysenteriae 
is known, then restriction enzymes can be Selected based on 
that Sequence. For example, the Sequence of a 2.3 kb HindIII 
target Sequence, shown in FIG. 1, indicates that there is one 
site where HindIII can cut the sequence. Other restriction 
enzymes can be selected that can cut the Sequence at one or 
more locations, preferably at about 1 to 3 locations, as 
shown in Table I. 
TABLE I 
AccI Aci Alu Alw AlwNI Apo 
Ava Bby Bcc BcgI Bfa BSeRI 
BSI BSmI BsmAI BSmBI BSOFI BspMI 
BSr. BSrBI BSFI BSrGI Cac8 CeI 
CePI Cvil Cvr Dde DpnI Dra 
Eae Ear Eci EcoS7 Econ EcoRI 
EcoRI GdIII Hae HindIII Hinf Hph I 
Mae Mbo Mme Mn Mise Ms 
MspI MspAII Mwo NaIII Nsi NspI 
Pst Pwl RsaI Sau6 Sau3AI SexAI 
SfaNI SfcI SspI Taq I Taq II TI 
Tse Tsp5091 Tth VspI 
The digested DNA is then contacted with a probe that can 
hybridize to a target Sequence Specific for at least one 
serotype of S. hyodysenteriae under conditions of hybrid 
ization for a probe of that size and/or Sequence complemen 
tarity as described previously. The hybridization conditions 
can be modified as necessary depending on the method of 
detection of hybrid formation employed including slot blot, 
dot blot, and/or Southern blot hybridization. The probes are 
preferably labeled for ease of detection of hybrid formation. 
In a preferred version, DNA is extracted from a biological 
Sample Such as from an animal Suspected of being infected 
with S. hyodysenteriae or from an environmental Sample 
Suspected of containing S. hyodysenteriae and the extracted 
DNA is digested with HindIII. The digested DNA extract is 
optionally Separated and contacted with a probe that can 
hybridize to a target Sequence Specific for S. hyodysenteriae 
such as a 2.3 kb HindIII restriction fragment of FIG.1. The 
preferred probe has a Sequence as follows: 
Sense-5'-TAGGGGCTGCTGTTCTAGCTGTAAATGC 
(SEQ ID NO:5) 
and is detectably labeled. The presence of S. hyodysenteriae 
is detected by the detection of hybridization of the probe to 
digested fragments from the biological Sample. Methods of 
detection of hybrids can be utilized depending on the labeled 
moiety that is attached to the probe, and are Standard 
methods. This method can also be used to distinguish S. 
hyOdysenteriae from at least one other microorganism. 
2. Recombinant Expression Vectors and Transformed Cells 
A target nucleotide Sequence that allows for identification 
of at least one Serotype of S. hyodysenteriae can be cloned 
into an expression vector and introduced into Suitable host 
cells to form transformed cells. The transformed cells car 
rying an expression vector are useful for amplification of all 
or a portion of a target Sequence to provide a probe, to 
provide any gene products encoded by the target Sequence, 
and/or as vaccine formulations. 
A target Sequence, Such as all or a portion of a 2.3 kb 
HindIII partial digest fragment from S. hyodysenteriae B204 
(SEQ ID NO:1), can be cloned into a suitable expression 
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vector such as puC18, pKC30, pBR322, pKK177-3, pET-3, 
and the like by standard methods. Commercially available 
expression vectors provide for cloning for a target Sequence 
into a site of the vector Such that the target Sequence is 
operably linked to transcriptional and translational control 
regions. It is preferred, but not required, that a target 
Sequence is operably linked to an inducible promoter Such as 
the PL promoter, the lac promoter, the tac promoter, or the 
T, promoter, and the like. 
The expression vectors can then be introduced into Suit 
able host cells using methods Such as calcium phosphate 
precipitation, lipoSome mediated transformation, protoplast 
transformation, electroporation, and the like. Suitable host 
cells include E. coli strains Such as E. coli DH5C, and 
avirulent isogenic Salmonella spp. Such as S. typhimurium 
deletion mutants lacking adenylate cyclase and cAMP 
receptor protein, Salmonella mutants in aro genes, and other 
Salmonella vaccine strains as described in Bio/Tech, 6:693 
(1988), and the like. 
Transformed cells can be screened by a variety of meth 
ods including colony hybridization or reactivity with anti 
bodies specific for S. hyodysenteriae B204. A transformed 
cell is an E. coli DH5O. cell carrying a puC18 plasmid with 
a 2.3 kb HindIII restriction fragment insert from S. hyodys 
enteriae B204. A pUC18 plasmid carrying a 2.3 kb HindIII 
insert from S. hyodysenteriae B204 designated pRED3C6, 
deposited with the American Type Culture Collection in 
Rockville, Md. has Accession No. 75826. 
3. Method for Detection of S. hyodysenteriae in a Biological 
Sample 
According to the invention, a biological Sample may be 
analyzed for the presence of S. hyodysenteriae by detecting 
the presence of DNA amplification products from primers 
that hybridize to a 2.3 kb HindIII partial digest restriction 
fragment of S. hyodysenteriae B204 serotype 2. Compared 
to other detection methods presently known and used, the 
invention advantageously provides a method that is highly 
Sensitive in detecting at least one Serotype of S. hyodysen 
teriae in a biological Sample when it is present in very low 
concentration, for example, about 1 to 10 organisms per 0.1 
gm sample. It is preferred that an about 1.55 kb DNA 
Sequence that lies between two regions of the about 2.3 kb 
HindIII Sequence is amplified. That Sequence is unique to all 
Serotypes of S. hyodysenteriae, and provides for the Specific 
detection of the Spirochete from other closely-related micro 
organisms including other members of the order Spirocha 
etales. Thus, this method is also useful to distinguish S. 
hyOdysenteriae from at least one other microorganism. 
In brief, the DNA amplification products can be detected 
by (a) extracting DNA from a biological Sample; (b) ampli 
fying a target Sequence of the extracted DNA to provide 
DNA amplification products carrying a Selected target DNA 
Sequence; and (c) detecting the presence of S. hyodysente 
riae by detecting the presence of the DNA amplification 
products. 
The biological Sample may be, for example, feces, 
mucosal Secretion, mucosal Scrapings, mucosal cells, rectal 
Swabs, intestinal wall, intestinal contents, local lymph 
nodes, and the like. The biological Sample may be derived, 
for example, from an animal infected with S. 
hyOdysenteriae, an animal Suspected of being a carrier of S. 
hyOdysenteriae, an animal being treated for an infection 
caused by S. hyodysenteriae. The biological Sample can also 
be an environmental Sample Such as manure, manure 
contaminated Soil, fomites, pits, lagoon water, or effluent 
from a premises Suspected of containing S. hyodysenteriae. 
Animals susceptible to infection with S. hyodysenteriae 
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include Swine, ratites (Such as rheas), rodents such as rats 
and mice, dogs, birds, poultry, and other wildlife. 
The detection method can also be optionally combined 
with methods for isolation of microorganisms to provide for 
confirmation of infection with S. hyodysenteriae and/or to 
increase the Sensitivity of the assay. For example, S. hyod 
ySenteriae present in a biological Sample could be separated 
from other biological material using an antibody attached to 
a Solid Support Such as a monoclonal antibody attached to 
immunomagnetic particle, as described by Islam et al., J. 
Clin. Micro., 30:2801 (1992). The isolated S. hyodysenteriae 
can then be detected using the polymerase chain reaction as 
described herein. 
In a preferred method, the amplification of the DNA 
Sequence is by polymerase chain reaction (PCR), as 
described in U.S. Pat. No. 4,683,202 to Mullis; Mullis et al., 
Cold Spring Harbor Symp. Quanti. Biol. 51:263 (1896); 
Mullis and Faloona, Methods Enzymol. 155:335 (1987); 
Saiki et al., Science 239:487 (1988b); and Chien et al., J. 
Bacteriol. 127:1550 (1976). In brief, the DNA sequence is 
amplified by reaction with at least one oligonucleotide 
primer or pair of oligonucleotide primers that hybridize to 
the target Sequence or a flanking Sequence of the target 
Sequence and a DNA polymerase to extend the primer(s) to 
amplify the target Sequence. The amplification cycle is 
repeated to increase the concentration of the target DNA 
Sequence. 
The biological Sample is first treated to extract a nucleic 
acid Sequence Specific to S. hyodysenteriae, which may be 
either mRNA or DNA. The nucleic acid fragments may be 
extracted from the biological Sample by Standard methods as 
described in Elders et al., cited Supra. Either purified chro 
mosomal DNA or total DNA or total mRNA is extracted 
from the biological Sample for amplification and detection. 
In addition, the polymerase chain reaction may be used to 
amplify cl)NA that has been synthesized in vitro by reverse 
transcriptase of an mRNA template, according to Standard 
methods. The mRNA that is extracted from the biological 
Sample for Synthesis of cDNA sequence is Suspected of 
including a messenger RNA that is complementary to a 
target Sequence Such as a 2.3 kb HindIII partial digest 
restriction fragment of S. hyodysenteriae B204. Primers 
useful to generate cDNA can be designed as described 
previously. 
Other methods of polymerase chain reaction using various 
combination of primers including a single primer to about 3 
primers are known to those of skill in the art and are 
described in Maniatis, cited Supra. Those methods include 
asymmetric PCR, PCR using mismatched or degenerate 
primers, reverse transcriptase PCR, arbitrarily primed PCR 
(Welsh et al., Nucleic Acids Res., 18:7213 (1990)), or RAPD 
PCR, IMS-PCR (as described by Islam et al., J. Clin. Micro, 
30:2801 (1992)), multiwell PCR (ELOSA) (as described by 
Luneberg et al., J. Clin. Micro. 31:1088 (1993) and Katz et 
al., Am. J. Vet. Res., 54:2021 (1993). The methods also 
include amplification using a Single primer as described by 
Judd et al., Appl. Env: Microbiol., 59: 1702 (1993). 
The nucleotide Sequences are recovered from the biologi 
cal Sample So as to be Substantially free of Substances that 
may interfere with the enzymatic amplification procedure, as 
for example, enzymes, low molecular weight Substances 
Such as peptides, proteins, lipids, carbohydrates, and the 
like. Such methods are known and used in the art. 
In a preferred version, an oligonucleotide primer pair that 
can hybridize to the 2.3 kb HindIII restriction fragment of S. 
hyodysenteriae B204 shown in FIG. 1 are mixed with 
deoxynucleotides, Taq polymerase, and the extracted DNA 
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or CDNA. Initial denaturing is at 95 C. for 60 seconds 
followed by 30 cycles with 60 seconds at 65° C. and 120 
Seconds at 72 C. Amplified products are optionally sepa 
rated by methods Such as agarose gel electrophoresis. The 
amplified products can be detected by either Staining with 
ethidium bromide silver stain or by hybridization to a probe 
as described previously. The preferred oligonucleotide 
primer pairs amplify a portion of the target Sequence of S. 
hyodysenteriae B204 of FIG. 1 to form an about 1.5 kb 
amplification product. 
In an alternative embodiment, at least one probe that 
hybridizes to the amplified products is labeled with a biotin 
moiety and/or at least one probe labeled with fluorescently 
labeled probe. The hybrids are then bound to a solid support 
Such as a bead, multiwell plate, dipStick or the like that is 
coated with streptavidin. The presence of bound hybrids can 
be detected using an antibody to the fluorescent tag conju 
gated to horseradish peroxidase. The enzymatic activity of 
horseradish peroxidase can be detected with a colored, 
luminescent or fluorimetric Substrate. Conversion of the 
Substrate to product can be used to detect and/or measure the 
presence of S. hyodysenteriae PCR products. 
An oligonucleotide primer preferably has a gene Sequence 
that hybridizes to a sequence flanking one end of the DNA 
Sequence to be amplified. The DNA sequence to be ampli 
fied is located adjacent the attachment of the Single primer, 
or between the attachment of the two primers. In the use of 
a pair of oligonucleotide primers, each of the primerS has a 
different DNA sequence and hybridizes to Sequences that 
flank either end of the target Sequence to be amplified. 
Design of primers and their characteristics have been 
described previously. The preferred DNA sequence of the 
Oligonucleotide prime r is positive - Sense 
5'-GGTACAGGCGGAAACAGACCTT (SEQ ID NO:3), or 
negative-sense 5'-TCCTATTCTCTGACCTACTG (SEQ ID 
NO:4), or a complement thereof, or a mixture thereof. The 
primer may also be a degenerate primer that hybridizes to 
the target gene Sequence under hybridization conditions for 
a primer of that size and Sequence complementarity. 
For the binding and amplification, the sample DNA is 
provided in an aqueous buffer formulated with an effective 
amount of a divalent cation which is preferably MgCl, 
preferably at a concentration of about 0.05–5mM; an effec 
tive amount of DNA polymerase with Taq DNA polymerase 
being preferred in the form of native purified enzyme or a 
Synthesized form Such as Ampli-Taq (available commer 
cially from Perkin-Elmer Cetus Corp., San Francisco, Calif.) 
an effective amount of dNTPs as a nucleotide Source, 
including, dATP, dCTP, dGTP and dTTP, preferably in a 
Saturating concentration, preferably about 200 uM per 
dNTP; and an effective amount of one or a pair of oligo 
nucleotide primers. The reaction mixture containing the 
annealed primer(s) is reacted with a DNA polymerase at 
about 72 C for about 1-10 minutes, preferably about 3-5 
minutes, to extend the primers to make a complementary 
Strand of the target gene Sequence. The cycle is then repeated 
by denaturing the DNA Strands with heat, annealing and 
extending, preferably for about 25-40 cycles, preferably 
about 30 cycles. 
The major resulting product is preferably an about 1.55 kb 
gene Sequence which termini are defined by the oligonucle 
otide primer(s), and whose length is defined by the distance 
between the two primers or the length of time of the 
amplification reaction. The gene Sequence then Serves as a 
template for the next amplification cycle. 
The amplified DNA products are optionally separated 
from the reaction mixture and then analyzed. The amplified 
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gene Sequences may be visualized, for example, by Sepa 
rating the gene Sequences from undesirable Side-products 
and unreacted reagents by electrophoresis in an agarose or 
polyacrylamide gel, by HPLC Separation in an ion eXchange 
column or size exclusion column, or by the ELOSA 
technique, and other like techniques known and used in the 
art. 
The amplified gene Sequence may be directly or indirectly 
labelled by incorporation of an appropriate visualizing label, 
as for example, a radioactive, calorimetric, fluorometric or 
luminescent Signal, or the like. In addition, the gel may be 
Stained before or after electrophoresis with a visualizing dye 
Such as ethidium bromide or silver stain wherein the result 
ing bands may be visualized under ultraViolet light. 
The amplified DNA products may also be detected by 
Southern blot assay, dot blot assay, Slot blot assay, or other 
like analysis, in which the amplified products are separated 
by electrophoresis on a polyacrylamide or agarose gel, 
transferred to a membrane Such as a nitrocellulose or nylon 
membrane, reacted with an oligonucleotide probe, and 
detected. The amplified products may also be detected by 
reverse blotting hybridization (dot blot) in which an oligo 
nucleotide probe Specific to the gene Sequence is adhered to 
a nitrocellulose or polyvinylchloride (PVC) support such as 
a multi-Well plate, and then the Sample containing labelled 
amplified product is added, reacted, washed to remove 
unbound Substance, and a labelled amplified product 
attached to the probe or the gene Sequence imaged by 
standard methods. For slot blot analysis, the DNA products 
may be applied to a nylon membrane using a microfiltration 
apparatus, and hybridized with a labelled oligonucleotide 
probe, as described by Standard methods. 
The PCR amplification products can be detected in a 
multiwell plate by hybridization to a probe Specific for S. 
hyodysenteriae such as described in ELOSA methods by 
Katz et al., cited Supra. For analysis of nucleic acids 
extracted from more than one biological Sample, amplified 
products of each extract may be placed Separately into a 
different well of a multi-well plate, such as a PVC plate, and 
coated with a capture molecule Such as Streptavidin. The 
amplified products Specific for S. hyodysenteriae in each 
well can be preferably detected by hybridization to a probe 
labelled with a moiety that provides for color change Such as 
a fluorescent-labelled probe. A multi-well plate format 
allows the Screening of many different biological Samples in 
a single plate and can be conducted because of the extreme 
sensitivity of the PCR assay for detection of 1 to 10 
organisms per 0.1 gram of feces or other biological Sample. 
A multi-Well format likewise allows for the Screening and 
quantitation of the target Sequence of a single Sample in a 
Series of dilutions. 
In those assays, the amplified products are hybridized 
with an oligonucleotide probe that hybridizes to the target 
gene Sequence. It is preferred that the oligonucleotide probe 
is hybridizable to an about 1.5 kb gene Sequence located 
within the about 2.3 kb HindIII partial digest restriction 
fragment of the chromosomal DNA of S. hyodysenteriae 
B204. The probe is hybridizable to all or a portion of the 
gene Sequence under conditions Suitable for a probe of that 
Size and Sequence complementarity. The probe can distin 
guish from other microorganisms and cells in a biological 
Sample. Preferably, the oligonucleotide probe, Specific to S. 
hyodysenteriae has the Sequence: positive-Sense 
5'-TAGGGGCTGCTGTTCTAGCTGTAAATGC (SEQ ID 
NO:5). Other probes including detectably labelled probes 
may be prepared as described previously. 
ExceSS probe is removed from the reaction vessel or 
Support, for example, by Washing with a Suitable Solution. 
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The presence or absence of the DNA gene product is then 
determined by visualization of the label on the membrane or 
the vessel with an imaging System corresponding to the label 
that is used, including, for example, autoradiography, radia 
tion counting, X-ray, colorimetric, fluorometric or lumines 
cent Signal, and the like. 
The detection of amplified gene product in the Sample 
indicates the presence of S. hyodysenteriae in the biological 
Sample and in the animal. The method is useful in diagnos 
ing an S. hyodysenteriae infection in animals, and for 
detecting animals that are carrier-Shedders of S. hyodysen 
teriae in that they have no outward Signs of disease but carry 
the Spirochete internally and shed the organism in feces and 
other body materials and for detecting S. hyodysenteriae in 
environmental Samples contaminated with body fluids from 
infected animals. 
The amplification method is also useful for monitoring the 
efficacy of treatment for an infection caused by S. hyOdyS 
enteriae to ensure that Subclinically infected or carrier 
Shedder animals are not formed. For example, the assay may 
monitor the effectiveness of treatment of an animal with an 
antimicrobial agent Such as carbadox, tiamulin, lincomycin, 
arSanilic acid, chlortetracycline, Oxytetracycline, bacitracin, 
pyrantel tartrate, fenbendazole, gentamicin, neomycin, 
roXarSone, tylosin, Sulfamethazine, Virginiamycin, and the 
like, or a disinfection of the environment using agents Such 
as chlorhexidine, formaldehyde, creSols, phenols and qua 
ternary ammonium compounds among other treatments. In 
that method, biological Samples Such as feces, rectal Swabs, 
mucosal Scrapings, environmental Samples, and the like, are 
obtained from an animal under treatment for an infection 
caused by S. hyodysenteriae or the environment of the 
animal, and DNA amplification products of a target 
Sequence of S. hyodysenteriae from those Samples are ana 
lyzed for the presence of the S. hyOdysenteriae. Samples are 
obtained from the animal from time to time on a routine 
basis over the course of treatment, or afterwards, preferably 
about every day following treatment. The method can be 
used to monitor the efficacy of disinfection of equipment, 
fomites and the environment Surrounding an animal infected 
with S. hyodysenteriae. 
4. Vaccine. 
A56 kDa polypeptide and nucleotide Sequence of a 2.3 kb 
fragment of S. hyodysenteriae B204 shown in FIG. 1 are 
useful in formulating vaccines for immunizing animals 
against infection by S. hyodysenteriae. The polypeptide is 
also useful in Stimulating antibodies Specifically reactive 
with all the serotypes of S. hyodysenteriae and not with other 
closely related non-pathogenic intestinal Spirochetes. The 
vaccine contains an amount of the 56 kDa polypeptide 
effective to elicit a protective immune response against S. 
hyOdysenteriae in the animal, and achieving clinical efficacy, 
by Stimulating the production of antibodies specifically 
reactive with S. hyodysenteriae, exemplified by monoclonal 
antibody 10G6/G10 (available from Dr. Duhamel at Uni 
versity of Nebraska, Lincoln, Nebr.). The effectiveness of 
the vaccine is due, at least in part, to the conservative nature 
of the nucleotide Sequence encoding the 56 kDa polypeptide 
between different serotypes of S. hyodysenteriae and to its 
uniqueness to S. hyodysenteriae. 
The vaccine is composed of a Substantially pure, 56 kDa 
polypeptide encoded on an about 2.3 kb HindIII restriction 
fragment of the chromosomal DNA of S. hyodysenteriae, 
exemplified by the chromosomal DNA of S. hyodysenteriae 
isolate B204 shown in FIG. 1. The 56 kDa protein has a 
predicted amino acid sequence shown in FIG. 1 (SEQ ID 
NO:2). As used herein, the term “substantially pure” means 
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that the polypeptide has been extracted and isolated from its 
natural association with other proteins, lipids, and other like 
Substances from an appropriate host System. Preferably, the 
DNA fragment has the nucleotide sequence shown in FIG. 
1 (SEQ ID NO:1). 
The polypeptide may be produced, for example by incor 
porating the DNA restriction fragment into an expression 
vector, which includes the restriction fragment operably 
linked to transcriptional and translational control regions in 
the vector. The expression vector may then be used to form 
a transformed cell that includes the DNA fragment which 
can be used to produce the 56 kDa polypeptide, as described 
previously. The 56 kDa polypeptide has a predicted amino 
acid sequence as shown in FIG. 1 (SEQID NO:2). A plasmid 
designated pRED3C6 and carrying the 2.3 kb HindIII insert 
from S. hyodysenteriae B204 has been deposited with the 
American Type Culture Collection, Rockville, Md., and 
given Accession No. 75826. 
The polypeptide is administered in combination with a 
physiologically-acceptable, non-toxic, liquid carrier, com 
patible with the polypeptide and the animal. Suitable phar 
macological carriers include, for example, physiological 
saline (0.85%), phosphate-buffered saline (PBS), Tris 
(hydroxymethyl aminomethane (TRIS), Tris-buffered 
Saline, and the like. 
The vaccine may further include an adjuvant to enhance 
the immune response in the animal. Such adjuvants include, 
for example, aluminum hydroxide, aluminum phosphate, 
Freund's Incomplete Adjuvant (FCA), liposomes, ISCOMs 
(Mowat et al., Immunology Today, 12:383 (1991)), EMUL 
SIGEN PLUS, and the like. The vaccine may also include 
additives Such as buffers and preservatives to maintain 
isotonicity, physiological pH, stability, and Sterility. 
Parenteral and intravenous formulations of the vaccine may 
include an emulsifying and/or Suspending agent, together 
with pharmaceutically-acceptable diluents to control the 
delivery and the dose amount of the vaccine. Other additives 
may be included as desired, as for example, preservatives, 
buffering agents, and the like. 
The vaccine may be used for alleviating or minimizing the 
Symptoms of an infection caused by S. hyodysenteriae. The 
vaccine may be delivered to the animal, for example, by 
parenteral delivery, injection (Subcutaneous or 
intramuscular), oral, intrarectal, and the like, by known 
techniques in the art. For prophylactic and anti-infectious 
therapeutic use in Vivo, the vaccine contains an amount of 
the polypeptide to Stimulate a level of active immunity in the 
animal to inhibit and/or eliminate S. hyodysenteriae patho 
genesis. 
Factors bearing on the vaccine dosage include, for 
example, the age and weight of the animal. The range of a 
given dose is about 1 to 1000 ug of the purified polypeptide 
per ml, preferably about 50-200 tug/ml preferably given in 
about 1-5 ml doses. The vaccine should be administered to 
the animal in an amount effective to ensure that the animal 
will develop an immunity to protect against infection by S. 
hyodysenteriae. For example, for an about 20-30 lb Swine, 
a single dose of a vaccine made with Freund's incomplete 
adjuvant for Subcutaneous or intramuscular injection, would 
contain about 50-200 tug of the purified polypeptide per ml. 
Preferably, the vaccine is given in an about 1-5 ml dose 
before or at the time of weaning (2-4 weeks old). The 
immunizing dose would then be followed by a booster 
injection given at about 14-28 days after the first injection. 
The invention also provides for a vaccine formulation of 
a live avirulent microorganism transformed with a vector 
having a 2.3 kb DNA fragment insert from S. hyodysenteriae 
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B204 having a nucleotide sequence as shown in FIG.1. The 
fragment can be inserted in to a Suitable expression vector 
such as pYA292, as described previously. Plasmid pYA292 
carries a Salmonella origin of replication, an asd gene as the 
only Selectable marker gene, P, regulator/promoter, a ribo 
Some binding Site, and an ATG start codon followed by a 
multiple cloning Site and transcriptional terminators. Plas 
mid pYA292 is designed to express a recombinant antigen as 
a non-fusion protein. 
An expression vector carrying an insert can be trans 
formed into an avirulent immunogenic host cell Such as 
Salmonella spp. having attenuating mutations in genes 
encoding enzymes involved in the Synthesis of Vital metabo 
lites Such aro, cya, crp, and asd as described by Curtis et al., 
Infection and Immunity, 55:3035 (1987); Dugan et al., J. 
Infec. Dis., 158:1329 (1988); and Edwards et al., J. 
Bacteriol, 170:3991 (1988). These microorganisms have 
the capacity to elicit long-lasting humoral and cell mediated 
immunity at high levels of Safety. 
The Salmonella spp. transformed with a vector carrying a 
2.3 kb insert from S. hyodysenteriae can be screened for 
reactivity with antibodies to S. hyodysenteriae or by hybrid 
ization of DNA or mRNA to a probe specific for the 2.3 kb 
insert. Transformed Salmonella spp. producing a polypep 
tide encoded by the 2.3 kb insert (SEQ ID NO:1) can be 
further Selected for avirulence and for generating a protec 
tive immune response against S. hyodysenteriae in an ani 
mal. Animals include Swine, poultry, ratites, rodents, birds, 
rheas, and the like. The transformed microorganism that is 
avirulent and elicits a protective immune response against S. 
hyOdysenteriae infection in an animal is the preferred micro 
organism for the vaccine formulation. 
The microorganisms can be combined with carriers or 
adjuvants as described previously. The vaccine can be 
administered parenterally, e.g. Subcutaneously, intraperito 
neally or intramuscularly, orally or intra-rectally. Preferably, 
the vaccine is administered orally at least one and preferably 
at least two or more times at intervals of about 14 to 28 days. 
The amount of microorganism included in the vaccine 
formulation is an amount that is effective to generate a 
protective immune response against infection with S. hyo 
dysenteriae as determined by detecting a decrease in the 
mortality and/or Symptoms of disease caused by S. hyOdyS 
enteriae. The amount of microorganisms will depend, in 
part, on the route of administration and/or the animal to 
immunized. Preferably, an amount of microorganisms is 
about 10 to 10 CFU/ml and more preferably about 10 to 
10 CFU/ml. 
Passive Immunization 
The polypeptide may also be utilized to raise polyclonal 
antibody Sera and monoclonal antibodies for use in passive 
immunization therapies. Polyclonal antibodies may be 
raised to the polypeptide by hyperimmunizing an animal 
with an inoculum containing the isolated 56 kDa polypep 
tide. The blood serum may be removed and contacted with 
immobilized 56 kDa polypeptide reactive with the protein 
Specific antibodies. The Semi-purified Serum may be further 
treated by chromatographic methods to purify IgG and IgM 
immunoglobulins to provide a purified polyclonal antibody 
Sera for commercial use. 
Monoclonal antibodies reactive with the polypeptide may 
be raised by hybridoma techniques known and used in the 
art. In brief, a mouse, rat, rabbit or other appropriate Species 
may be immunized with the 56 kDa polypeptide. The spleen 
of the animal is then removed and processed as a whole cell 
preparation. Following the method of Kohler and Milstein 
(Nature 256:496–97 (1975)), the immune cells from the 
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Spleen cell preparation can be fused with myeloma cells to 
produce hybridomas. The hybridomas may then be cultured 
and the culture fluid tested for antibodies specific for the 56 
kDa polypeptide using, for example, an ELISA in which the 
56 kDa polypeptide is immobilized onto a solid surface and 
act as capture antigens. The hybridoma may then be intro 
duced into the peritoneum of the host Species to produce a 
peritoneal growth of the hybridoma, and ascites fluids con 
taining the monoclonal antibody Specific to the Spirochete 
may be collected. 
The monoclonal antibodies may be used in diagnostic and 
therapeutic compositions and methods, including passive 
immunization. Immunoglobulins Specific towards the 56 
kDa polypeptide may be used to provide passive immunity 
against an infection caused by S. hyodysenteriae. Animals 
may be treated by administering immunoglobulins intramus 
cularly at about 100/mg/kg body weight, about every 3-7 
days. 
Diagnostic Method 
Antibodies to the 56 kDa polypeptide may be used in an 
in vitro method of diagnosing an infection of S. hyodysen 
teriae in an animal. The diagnostic method includes con 
tacting a body material potentially containing S. hyodysen 
teriae Such as feces, mucosal Scraping, or other like tissue 
sample or body material with a labelled antibody raised to 
the 56 kDa polypeptide encoded on an about 2.3 kb HindIII 
restriction fragment of S. hyodysenteriae, and detecting the 
label in the complex formed between the polypeptide in the 
body material and the labelled antibody. The method may 
also be performed by combining the body sample with the 
antibody to the polypeptide, and then contacting the Sample 
with a labelled anti-species antibody reactive with the 
polypeptide-specific antibody, and then detecting the label. 
In addition, the 56 kDa polypeptide may be used as a 
capture antigen in a method of monitoring and profiling an 
infection caused by S. hyodysenteriae. For example, the 
polypeptide may be used in an ELISA technique by immo 
bilizing the polypeptide on a Solid Support Such as a poly 
Vinylchloride plate, and contacting the immobilized peptide 
with a Sample material to react with and detect antibodies 
present in the Sample. 
The invention further provides an in vitro assay for 
detecting S. hyodysenteriae-specific antibodies in a Sample. 
In that method, a Sample to be tested is contacted with a 
composition containing the about 56 kDa polypeptide, 
which is preferably labelled, to form a conjugate which is 
then detected. A method for diagnosing an infection by S. 
hyOdysenteriae in a biological Sample may be carried out 
with the polyclonal antibody Sera or monoclonal antibodies 
described hereinabove, in an enzyme-linked immunosorbant 
assay (ELISA), radioimmunoassay (RIA), immunofluores 
cent assay (IFA), a Northern, Western or Southern blot assay, 
and the like. In brief, the antibody or biological Sample (i.e., 
tissue sample, body fluid) may be immobilized, for example, 
by contact with a polymeric material Such as polystyrene, 
polyvinylchloride, a nitrocellulose paper, or other like Sup 
port means for immobilizing the antibody or Sample. The 
other antibody or biological Sample is then added, incubated, 
and the non-immobilized material is removed by Washing or 
other means. A labeled Species-specific antibody reactive 
with the later is added. The serum antibody or S. hyodys 
enteriae bacteria in the biological Sample, is then added and 
the presence and quantity of label is determined to indicate 
the presence and amount of S. hyodysenteriae bacteria in the 
biological Sample. 
5. Mutants of S. hyodysenteriae and Vaccine Composition 
Once a target Sequence Specific for S. hyodysenteriae and 
that can distinguish at least one Serotype of S. hyodysente 
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riae from other closely related microorganisms is identified, 
the target Sequence can be altered or mutated to form 
mutants of S. hyodysenteriae. An example of a target 
Sequence is found in all Serotypes of S. hyodysenteriae and 
not in other closely-related microorganisms is a 2.3 kb 
HindIII restriction fragment of S. hyodysenteriae serotype 
B204 having the nucleotide sequence shown in FIG. 1. S. 
hyodysenteriae B204 mutants with alterations in the 
Sequence shown in FIG. 1 can be generated using Standard 
methods. Mutants with alterations or deletions in this region 
can be selected for reduced virulence and/or the ability to 
Stimulate an immune response, preferably a protective 
immune response to infection with S. hyodysenteriae Sero 
types. These mutants can be useful in vaccine formulations 
and to elicit antibodies in animals without causing mortality. 
The antibodies elicited could be used for passive immuni 
Zation. 
Mutants of S. hyodysenteriae B204 with alterations in the 
2.3 kb HindIII restriction fragment can be generated using 
Standard methods Such as chemical mutagenesis (as 
described in U.S. Pat. No. 4,999,191 to Glisson et al.); 
transposon mediated mutagenesis (as described in U.S. Pat. 
No. 4,764,370 to Fields et al.); ultraviolet irradiation; and 
methods of site-specific mutagenesis (as described in Mania 
tis et al., cited Supra). 
Mutant microorganisms can be Screened for alteration to 
the target Sequence in a 2.3 kb HindIII restriction fragment 
using a variety of methods. The mutant can be Screened 
preferably for lack of production of a functional gene 
product encoded by a 2.3 kb HindIII restriction fragment by 
lack of reactivity with an antibody Specific for all or a 
portion of the polypeptide encoded by the fragment as 
exemplified by monoclonal antibody 10G6/G10 or poly 
clonal antibodies to the peptides, as described in Example 
VI. The mutants can also be screened for an inability to 
hybridize to a 2.3 kb HindIII restriction fragment probe or 
a change in the restriction enzyme fragments that hybridize 
to the probe. Other Screening methods, Such as using PCR 
and Sequencing of the mutated fragment, can also be 
employed. 
Alterations or mutations to the target Sequence include 
nucleotide Substitutions, deletions, additions (i.e., especially 
insertion of a transposon) in the 2.3 kb HindIII restriction 
fragment of serotype B204. Once mutants with alterations to 
the Sequence are identified, they can be further Selected for 
reduced virulence in animals and for the ability to elicit an 
immune response, preferably a protective immune response, 
using Standard methods. The especially preferred mutants 
have a deletion of a portion of a 2.3 kb HindIII restriction 
fragment, have reduced virulence for animals, and elicit a 
protective immune response that inhibits wild-type S. hyo 
dysenteriae infection with at least one Serotype of S. hyod 
ySenteriae. 
The mutants of the invention are useful to elicit antibodies 
in animals without causing mortality. These antibodies can 
be useful in methods of passive immunization as described 
previously. 
The mutants of the invention can also be useful in vaccine 
formulation. A vaccine formulation includes an amount of a 
mutant of S. hyodysenteriae having reduced virulence for 
animals effective to inhibit S. hyodysenteriae infection in 
animals, wherein the mutation is an alteration of a 2.3 kb 
HindIII restriction fragment of S. hyodysenteriae B204 in 
admixture with a physiologically acceptable carrier. The 
mutant microorganism is administered in combination with 
a physiologically acceptable, non-toxic liquid carrier com 
patible with the microorganism and the animal. Suitable 
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pharmacological carriers include, for example, physiologi 
cal saline (0.85%), phosphate buffered saline, Tris 
(hydroxymethylamino methane), Tris buffered Saline, and 
the like. 
The vaccine may further include an adjuvant to enhance 
the immune response in the animal. Such adjuvants include, 
for example, aluminum hydroxide, aluminum phosphate, 
Freunds incomplete adjuvant, liposome, ISCOMs, 
EMULSIGEN, and the like. The vaccine may also include 
additives Such as buffers and preservatives to maintain 
isotenicity physiological pH instability. Parental and intra 
venous formulations of the vaccine may include emulsifying 
and/or Suspending agent together with pharmaceutically 
acceptable diluents to control the delivery and dose amount 
of the vaccine. 
The vaccine may be used for alleviating or minimizing the 
Symptoms of disease caused by S. hyodysenteriae. The 
vaccine may be delivered to the animal, for example, by 
parental delivery, injection (Subcutaneous or intramuscular), 
or oral delivery by techniques known in the art. For pro 
phylactic and anti-infectious therapeutic use in Vivo, the 
vaccine contains an amount of the microorganism effective 
to Stimulate a level of active immunity in the animal to 
inhibit and/or eliminate S. hyodysenteriae pathogenesis. 
Factors bearing on the vaccine dosage include, for 
example, the age and weight of the animal. The range of a 
given dose is about 10 to 10' CFU of the microorganism 
per ml, preferably about 10 to 10 CFU/ml, preferably 
given in about 1 to 5 ml doses. The vaccine can be 
administered to the animal as a single dose but is preferably 
administered as 2 or 3 doses over an 8-10 week period. 
The invention will be further described by reference to the 
following detailed examples, wherein the methodologies are 
as described below. These examples are not meant to limit 
the scope of the invention that has been set forth in the 
foregoing description. Variation within the concepts of the 
invention are apparent to those skilled in the art. The 
disclosures of the cited references throughout the Specifica 
tion are incorporated by reference herein. 
EXAMPLE I 
Bacterial Culture and Growth Conditions 
Several genera of bacteria were cultured and grown to 
provide nucleic acid Samples for analysis by polymerase 
chain reaction and Southern blot hybridization with the 2.3 
kb HindIII DNA fragment of clone pRED3C6. 
1. Bacterial Strains. 
Serpulina hyodysenteriae strain B78 serotype 1 (ATCC# 
27164; Harris et al., Int. J. Syst. Bact., 29:102-109 (1979); 
and Kinyonet al., Infect. Immun., 15:638-646 (1977)), strain 
B204 serotype 2, strain B169 serotype 3, and strain A1 
serotype 4, were obtained from J. M. Kinyon, College of 
Veterinary Medicine, Iowa State University, Ames, Iowa. 
Reference S. hyodysenteriae strains B234 serotype 1, B8044 
serotype 5, B6933 serotype 6, AcK300/8 serotype 7 were 
provided by L. A. Joens, Department of Veterinary Science, 
University of Arizona, Tucson, Ariz. Reference Strains 
FM-88-90 serotype 8, FMV 89-3323 serotype 9 were pro 
vided by M. Jacques, Faculté de Médecine Vétérinaire, 
Université de Montréal, Saint-Hyacinthe, Québec, Canada. 
Li et al., J. Clin. Microbiol., 29:2794–2797 (1991). The 
reference isolates for WBHIS, Serpulina innocens, isolates 
B256 (ATCC#29796; and Harris et al., cited supra) and 4/71 
were obtained from the American Type Tissue Culture 
Collection, Rockville, Md., and T. B. Stanton, National Pig 
Disease Center, Ames, Iowa, respectively. 
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A total of 13 field isolates representing three genotypic 
groups of WBHIS distinct from S. innocens were obtained 
from porcine feces, porcine rectal Swabs, and porcine 
colonic mucosal Scrapings Submitted either to the Veterinary 
Diagnostic Center, University of Nebraska-Lincoln or Agri 
culture Canada, Saint-Hyacinthe, Québec. Lee et al., Vet. 
Microbiol, 34:35-46 (1993); and Ramanathan et al., Vet. 
Microbiol, 37:53–64 (1993). The WBHIS isolates B359 and 
B1555a were obtained from J. M. Kinyon, and isolate 
D9201243A was provided by R. L. Walker, California 
Veterinary Diagnostic Laboratory System, University of 
California, Davis, Calif. The WBHIS isolate 16 (ATCC# 
49776; Jones et al., J. Clin. Microbiol., 24:1071-1074 
(1986)) obtained from an HIV-positive homosexual male 
with diarrhea was provided by R. M. Smibert, Virginia 
Polytechnic Institute, Blacksburg, Va. In addition, species of 
other genera of bacteria were obtained and cultured accord 
ingly to Standard methods as described below. In Some 
instances, chromosomal DNA was obtained. 
Treponema succinifaciens, isolate 6091 (ATCC# 33096; 
Cwyk et al., Arch. Microbiol., 122:231-239 (1979)) and 
Bacteroides vulgatus (ATCC# 31376) were obtained from 
the American Type Tissue Culture Collection. Chromosomal 
DNA from Spirochaeta aurantia was provided by E. P. 
Greenberg, University of Iowa, Iowa City, Iowa. The Tre 
ponema pallidum chromosomal DNA was provided by M. V. 
Norgard, The University of Texas Health Science Center, 
Houston, Tex. Chromosomal DNA from representative 
Stains of each of the ten genetic groups in the family 
Leptospiraceae including Leptospira biflexa Serovars patoc, 
Semaranga, and codice, Leptospira interrogans Serovars 
icterohaemorrhagiae, fortbragg, ballum, celledoni, lyme, 
and borincana, and Leptonema illini Serovar illini were 
provided by R. L. Zuerner, National Pig Disease Center, 
Ames, Iowa. Chromosomal DNA from Borrelia burgdorferi, 
Campylobacter coli and C. hyointestinalis were provided by 
M. P. Murtaugh, University of Minnesota, St. Paul, Minn. 
Isolates of Salmonella choleraeSuis and S. typhimurium 
were provided by P. J. Fedorka-Cray, National Pig Disease 
Center, Ames, Iowa. The Escherichia coli DH5C. was pur 
chased from a commercial source (GIBCO-BRL, 
Gaithersburg, Md.). 
2. Medium and growth conditions. 
For isolation of DNA, cultures of Serpulina spp., WBHIS, 
and T. SuccinifacienS were propagated in pre-reduced 
anaerobically-sterilized (PRAS) trypticase soy broth supple 
mented with 0.5% (wt/vol) glucose (Sigma Chemical Co., 
St. Louis, Mo.), 0.05% (wt/vol) cysteine hydrochloride 
monohydrate (Sigma), 1.0% (wt/vol) yeast extract (BBL 
Microbiology Systems, Becton Dickinson and Co., 
Cockeysville, Md.), 2.0% (v/v) bovine fetal serum (HyClone 
Laboratories, Inc., Logan, Utah), 0.2% (wt/vol) sodium 
bicarbonate and 5.0% (v/v) sterile porcine fecal extract as 
described by Kunkle et al., J. Clin. Microbiol., 24:669-671 (1986), except that 1% (vol/vol) of room air was injected at 
the time of inoculation (Stanton et al., Vet Microbiol., 
18:177-190 (1988)). Broth cultures were grown to late 
logarithmic phase in 5 ml Volumes in Hungate tubes or in 
250 ml volumes in serum bottles. Cultures were stirred 
constantly using a magnetic stirrer at 37 C. under a 10% 
hydrogen, 10% carbon dioxide and 80% nitrogen atmo 
sphere for 48 to 72 hours. Cultures of Salmonella spp., 
Bacteroides vulgatus and Escherichia coli were grown at 
37 C. with shaking in Luria-Bertani broth to late logarith 
mic phase. 
Chromosomal DNA was purified as previously described 
by Ramanathan et al., Vet. Microbiol, 37:53-64 (1993), 
except that the final pellet was resuspended in Sterile HO to 
a final concentration of 12.5 ng/ul. 
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EXAMPLE II 
Library Construction and Recombinant Screening 
A library of S. hyodysenteriae isolate B204 in E. coli 
DH5O. was constructed. 
1. Preparation of the DNA Library. 
Serpulina hyodysenteriae isolate B204 and weakly 
B-hemolytic intestinal spirochetes of Swine; isolates B359 
and B1555a (courtesy of J. M. Kinyon, College of Veteri 
nary Medicine, Iowa State University, Ames, Iowa); Ser 
pulina innocens isolate B256 (American Type Culture 
Collection, Rockville, Md.); and E. coli strain DH5C. (Bethesda Research Laboratories, Inc., Gaithersburg, Md.) 
were used. Serpulina spp. and other Spirochetes were propa 
gated in FS medium (Kunkle et al., J. Clin. Microbiol., 
24:669–671 (1986)) to a density of 10 to 10° cells per ml 
at 37° C. 
DNA was isolated, by a modification of a previously 
reported method (Caputa et al., J. Clin. Microbiol., 
29:2418–2413 (1991)), from a 500 ml culture of S. 
hyodysenteriae, isolate B204. Briefly, spirochetes were 
centrifuged, washed twice in 100 ml of TE buffer (10 mM 
Tris-HCl pH 8.0), 1 mM Na-EDTA pH 8.0), and resus 
pended in 25 ml of 50 mM Tris-HCl (pH 8.0), 50 mM 
Na-EDTA (pH 8.0). N-lauroylsarcosine was added to a final 
concentration of 2% (wt/vol), followed by the addition of 
100 tug/ml of proteinase K. The mixture was incubated at 56 
C. for 16 hours. Phenylmethylsulfonyl fluoride was added to 
a final concentration of 1 mM and the mixture was incubated 
at room temperature for 10 minutes, then the Solution was 
mixed with 0.1 Volume of 7.5M ammonium acetate, and the 
DNA was precipitated with 2 volumes of ethanol. The DNA 
precipitate was recovered on a glass rod, washed with 70% 
ethanol, resuspended in TE buffer to a concentration of 0.5 
to 1 lug/ul and stored at -20° C. until needed. 
Standard cloning protocols were used for DNA manipu 
lations. Sambrook et al., Molecular Cloning. A Laboratory 
Manual, 2nd ed., Cold Spring Harbor Laboratory, Cold 
Spring Harbor, N.Y. (1989). Purified chromosomal DNA 
from S. hyodysenteriae, isolate B204 was incompletely 
digested with HindIII (Stratagene, Lajolla, Calif.) and 4 kb 
to 9 kb fragments were obtained by centrifugation on a 5% 
incremental Sucrose gradient with a range of 10 to 40%. 
After dialysis against TE buffer, the DNA fragments were 
ligated with T4 DNA ligase (Stratagene, LaJolla, Calif.) to 
plasmid vector puC18 (Bethesda Research Laboratories, 
Inc., Gaithersburg, Md.) dephosphorylated with calf intes 
tinal alkaline phosphatase (Bethesda Research Laboratories, 
Inc., Gaithersburg, Md.). E. coli, strain DH5O. cells were 
transformed with the ligation mix and recombinant clones 
were Selected by growth on Luria-Bertani (LB) agar con 
taining 100 ug/ml amplicillin (Bethesda Research 
Laboratories, Inc., Gaithersburg, Md.), 12 tug/ml isopropyl 
f3-D-thiogalactosidase (IPTG) (Bethesda Research 
Laboratories, Inc., Gaithersburg, Md.), and 40 ug/ml 
5-bromo-4-chloro-3-indoyl-f-D-galactoside (X-gal) 
(Bethesda Research Laboratories, Inc., Gaithersburg, Md.). 
Replica plating was executed by transferring colonies to 
nitrocellulose membranes (HAFT, 0.45 um pore size) (Millipore Corp., Bedford, Mass.). 
Transformed E. coli DH5a cells were screened with 
monoclonal antibodies, such as 10G6/G10, by colony 
immunoblotting. These monoclonal antibodies can be pre 
pared as described in Example VI or are available from Dr. 
Duhamel, University of Nebraska, Lincoln, Nebr. A mono 
clonal antibody used for Screening has been designated 
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10G6/G10 and is an IgM antibody that is specific for cell 
free Supernatants derived from S. hyodysenteriae. Briefly, 
replica membranes (Millipore cat. #HATF13750, Millipore 
Corp., Bedford, Mass.) were lysed in chloroform vapor 
followed by overnight incubation in lysis/blocking solution 
(5% nonfat dry milk, 0.5M MgCl, 40 mg/ml lysozyme, 100 
mg/ml chloramphenicol, 2 mg/ml DNase) at room tempera 
ture. Membranes then were incubated Sequentially at room 
temperature with ascites fluid for 2 hours, followed by 
biotin-labeled goat anti-mouse IgA+IgG+IgM(H+L) anti 
body (Kirkegaard and Perry Laboratories Inc., Gaithersburg, 
Md.) for 1 hour, peroxidase-labeled Streptavidin (Kirkegaard 
and Perry) for 45 minutes, and 4-Chloro-1-Naphthol 
(Kirkegaard and Perry) for 5 minutes. Five 5-minute washes 
with wash buffer (1M Tris-base, 2M NaCl, 5% nonfat dry 
milk and 0.05% NP-40 (pH 7.5)) were performed between 
each incubation Step. One immunopositive clone, designated 
pRED3C6, was identified based on development of a dark 
purple precipitate. 
EXAMPLE III 
DNA Sequencing and Primer Selection 
The immunopositive clone was amplified and the plasmid 
DNA with insert was isolated and sequenced. The insert was 
identified as about a 2.3 kb HindIII partial digest fragment. 
The nucleotide Sequence of the 2.3 kb insert fragment was 
used to design primers. 
1. Plasmid and insert DNA isolation and Sequencing 
The recombinant plasmids were isolated (MagicTM 
Minipreps, Promega Corp., Madison, Wis.), digested with 
the restriction enzyme HindIII (GIBCO-BRL), and the DNA 
fragments separated by electrophoresis in a 0.8% agarose gel 
using TAE running buffer (16 mM Tris-base, 8 mM sodium 
acetate, and 1 mM EDTA, pH 7.5) containing 0.66 ug of 
ethidium bromide per ml. The resulting bands were visual 
ized and photographed under ultraViolet light with a 
Polaroid MP 4 land camera. Recombinant DNA bands were 
excised from the gels with a razorblade, isolated (Geneclean 
II, BioRad, Richmond, Calif.), and subjected to the restric 
tion enzymes AccI, AluI, EcoRI, DraI, Hae|II, SspI and Xbal 
(GIBCO-BRL). Resulting fragments were purified and Sub 
cloned into the vector pUC18 for Sequencing using a Model 
1O 
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4,000 DNA sequencer (Li-Cor, Inc. Lincoln, Nebr.). 
Sequencing data were analyzed and assembled using the 
Program manual for the GCG Package Version 7, Apr. 1991 
from the Genetics Computer Group (1991). Results are 
shown in FIG. 1. 
Presence of -10 and -35 sequences along with a probable 
ribosomal binding site upstream from the transcription Start 
codon of the gene Suggested a single protein transcript. 
Analysis of the deduced amino acid sequence of the ORF for 
prediction of a membrane translocation Signal failed to 
identify any significant homology with other known 
N-terminal export Signal Sequences. However, the 
C-terminal Sequence of the gene contained a highly charged 
amino acid followed by a Ser Thr-rich amphophilic region 
Suggestive of an extracellularly Secreted protein. Lory, J. 
Bacteriol, 174:3423-3428 (1992). The sequence encodes a 
polypeptide with a predicted molecular weight of a 56 kDa 
protein. The nucleotide Sequence may also encode related 
polypeptides of Smaller molecular weight that could be 
post-translationally processed. 
Furthermore, comparisons of the DNA sequence of the 
recombinant 2.3-kb DNA fragment of pRED3C6 with the 
Sequences of the tly A gene (Muir et al., Infect. Immun., 
60:529–535 (1992)), tiy B, and tly C gene of S. hyodysen 
teriae (A. Agnes H. M. ter Huurne, Ph.D. Dissertation, 
University of Utrecht, Utrecht, Netherlands, (1993)), and the 
fla A gene of Koopman et al., Inf and Imm., 60:2920 (1992) 
indicated that these Sequences had less than 45% nucleotide 
Sequence identity and less that 25% amino acid identity. The 
nucleotide and amino acid Sequences were also compared 
with nucleotide Sequences encoding a 39 kDa protein from 
S. hyodysenteriae, shown in ML Technology Ventures’ PCT 
Application No. WO91/04036 published Apr. 4, 1991, and 
had less than 47% DNA sequence identity and less than 25% 
amino acid identity. A comparison to Sequences published in 
EP0350715 also showed less than 45% DNA sequence 
identity and less than 20% amino acid identity. The nucle 
otide Sequence comparison also revealed in most cases that 
there were little or no regions of contiguous Sequence 
identity of greater than 10 base pairs. The Sequence com 
parisons were conducted using GCG Package, version 7.3, 
Jun. 1993 (Genetics Computer Group, Madison Wis.). See 
Table II. 
TABLE II 
Sequence analysis comparisons between 
the 2.3-kb fragment of clone prED3C6 and sequences currently available.t 
Sequence 
Muir et al., 1992 
Ter Huurne et al., 1993 
Ter Huurne et al., 1993 
Koopman et al., 1993 fla A 
ML Tech. Vent, 1991 
ML Tech. Vent, 1990 
Amino acid Nucleotide 
Gene %. Similarity 96 Identity 96 Identity GAPs 
tly A 55.7 24.4 44.5 8 
tly B 45.4 19.9 42.2 16 
tly C 42.O 19.5 44.4 2O 
42.6 14.8 44.1 11 
Copy #1 42.9 18.2 44.6 
Copy #2 47.1 19.9 43.2 
Copy #3 44.7 19.8 44.4 
Copy #4 43.3 17.2 43.6 
Copy #5 42.9 19.0 43.1 
Copy #6 42.8 18.8 41.2 
Copy #7 42.9 21.6 45.O 
Copy #8 43.7 19.8 46.5 
38 kDa 46.0 17.0 42.O 
60 kDa 43.6 18.4 41.7 
iCap, In: Genetics Computer Group. 1991. Program Manual for the GCG Package, Version 7.3, 
June 1993, 575 Science Drive, Madison, Wisconsin 53711, p. 5-27 to 5–53. 
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Additionally, an exhaustive search of the EMBL database 
failed to identify any sequence with significant DNA or 
amino acid homology with the recombinant 2.3 kb HindIII 
DNA fragment and its deduced amino acid Sequence. 
While not meant to limit the invention in any way, there 
is evidence that the 56 kDa polypeptide encoded by the 
recombinant 2.3 kb DNA fragment of pRED3C6 represents 
a putative S. hyodysenteriae hemolysin distinct from those 
described previously. This evidence indicates that transfor 
mation of a non-hemolytic E. coli host with pRED3C6 
conferred hemolytic activity to the E. coli host. Cleavage 
and subcloning of the ORF of the recombinant 2.3 kb DNA 
fragment resulted in complete loSS of hemolytic activity of 
the E. coli host. The fact that the 2.3 kb DNA sequence 
reacts Specifically with all the Serotypes of S. hyodysenteriae 
and none of the non-pathogenic intestinal Spirochetes further 
indicates that it may be associated with a virulence deter 
minant of S. hyodysenteriae Such as hemolysin. 
2. Southern blotting 
Approximately 2 tug of chromosomal DNA from S. hyo 
dysenteriae serotypes 1 to 7, S. innocens isolates B256 and 
4/71, WBHIS isolates B359 and B1555a and T. Succinifa 
ciens were digested with HindIII, electrophoretically Sepa 
rated on a 0.8% agarose gel, and transferred by capillary 
diffusion as described by Southern et al., J. Mol. Biol., 
98:503–517 (1975), to nylon membranes (HybondTM-N, 
Amersham, Arlington Heights, Ill.). Prehybridization, 
hybridization, and washing steps with a recombinant DNA 
fragment (2.3 kb) obtained from the immunopositive clone 
pRED3C6 labelled with O-P dCTP using an oligolabel 
ing kit (Pharmacia LKB Biotechnology, Piscataway, N.J.) 
were performed as described by Ramanthan et al., Vet. 
Microbiol, 37:53-64 (1993). For slot blot analysis purified 
genomic DNAS from cultivable reference isolates of the 
order Spirochaetales including S. hyodysenteriae Serotypes 1 
through 9, S. innocens isolates B256 and 4/71, 16 isolates of 
WBHIS belonging to 3 genotypic groups distinct from S. 
innocenS, Spirochaeta aurantia, Treponema spp., Borrelia 
burgdorferi, and representatives of each of the 10 genetic 
groups of the family Leptospiraceae, as well as enteric 
bacteria including Escherichia coli, Salmonella spp., 
Campylobacter spp., and Bacteroides vulgatus were applied 
to nylon membranes (Zeta-probe TM, Bio-Rad) using a 
microfiltration apparatus (Bio-Dot SF(R), Bio-Rad). 
Prehybridization, hybridization and washing steps with a 
recombinant DNA fragment obtained from the immunopo 
sitive clone pRED3C6 labelled with o-'P dCTP were 
carried out as described Ramanthan et al., Vet. Microbiol., 
37:53-64 (1993). The results are shown in FIG. 2. 
Southern blot hybridization of o-'PdCTP labelled 2.3- 
kb fragment from clone pRED3C6 yielded a strong hybrid 
ization signal with chromosomal DNA from reference iso 
lates of S. hyodysenteriae serotypes 1 through 7, but not with 
S. innocens isolates B256 and 4/71, WBHIS isolates B359 
and B1555a, and T. Succinifaciens (FIG. 2). When the same 
probe was reacted with chromosomal DNAS obtained from 
other cultivable reference isolates of the order Spirocha 
etales as well as enteric bacteria including Escherichia coli, 
Salmonella spp., Campylobacter spp., and Bacteroides Vul 
gatus in a slot blot hybridization assay, a Specific Signal was 
observed only with chromosomal DNA obtained from ref 
erence isolates of S. hyodysenteriae Serotypes 1 through 9. 
3. Primers and internal probe for PCR and Southern blot 
analysis 
An oligonucleotide primer pair (positive-sense 
5'-GGTACAGGCGGAAACAGACCTT (SEQ ID NO:3) 
and negative-sense 5'-TCCTATTCTCTGACCTACTG 
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(SEQ ID NO:4)) and an internal S. hyodysenteriae-specific 
oligo nucleotide probe (positive - Sense 
5'-TAGGGGCTGCTGTTCTAGCTGTAAATGC (SEQ ID 
NO:5)) were designed and synthesized (Integrated DNA 
Technologies, INC. Coralville, Iowa) based on results of 
DNA sequence analysis of the recombinant DNA fragment 
of the immunopositive clone pRED3C6. The primers were 
used for amplification either of purified chromosomal DNAS 
or total DNA extracted by the method described in Example 
I and Example V either from normal porcine feces inocu 
lated with S. hyodysenteriae cells, or from porcine feces, 
porcine rectal Swabs, and porcine colonic mucosal Scrapings 
obtained from Swine with clinical an infection caused by S. 
hyOdysenteriae. 
PrimerS or probes can be designed based on the Sequence 
of 2.3 kb HindIII fragment shown in FIG. 1. Primers can be 
designed using primer Search algorithms Such as Primer 
Detective (Clontech Laboratories, Inc., Palo Alto, Calif.). 
Probes can be designed using OLIGO Computer Program 
(Rychlik and Rhoades, “A Computer Program for Choosing 
Optimal-Oligonucleotides for Filter Hybridization, 
Sequencing and In Vitro Amplification of DNA”, Nucleic 
Acid Res., 17:8543–8551 (1989) or other commercially 
available computer Software with Similar applications. 
EXAMPLE IV 
Analysis of PCR Products from Several Strains of 
Bacteria 
The primers designed as described in Example III were 
used to amplify either purified chromosomal DNA or total 
DNA extracted from normal porcine feces inoculated with S. 
hyodysenteriae cells or porcine feces, porcine rectal Swabs, 
and porcine colonic mucosal Scrapings obtained from Swine 
with an infection caused by S. hyodysenteriae. The PCR 
products were analyzed by hybridization to an internal probe 
as described in Example III. 
The DNA was amplified using a hot start PCR as 
described by the manufacturer (GeneAmpTM PCR System 
480, Perkin Elmer, Norwalk, Conn.) in a total volume of 75 
all containing 4 mM MgCl2, 1x of PCR buffer; 0.2 mM of 
each DATP, dCTP, dGTP, dTTP (Perkin-Elmer Cetus): 75 
pmol of primers; and 1.5 U of Taq DNA polymerase 
(Perkin-Elmer Cetus) in sterile filtered autoclaved water. 
Initial denaturing was for 60 S at 95 C., followed by 30 
cycles (60s at 65° C. and 120s at 72° C.). The amplified 
products were visualized in 1.25% agarose gels ran at 3 
V/cm and stained with ethidium bromide. Southern blots 
were prehybridized and hybridized each for 1 hour at 
T-10 C. with an internal S. hyodysenteriae-specific oli 
gonucleotide probe 5'-end labelled withy-PATP using T4 
polynucleotide kinase (Pharmacia) as described by Maniatis 
et al., Molecular Cloning. Laboratory Manual, Cold Spring 
Harbor Laboratory, Cold Spring Harbor, N.Y. (1982). 
Washes consisted of 1x SSPE (3.6M NaCl, 0.2M NaH2PO, 
0.02M EDTA, pH 7.7) with 0.1% SDS (3 times for 5 min at 
room temperature and once for 5 min at T-10 C.). The 
membranes were exposed to X-OMATAR Cronex radio 
graph film (Eastman Kodak Company, Rochester, N.Y.) in a 
cassette with lightning plus intensifying Screens (DuPont, 
Wilmington, Del.) at -70° C. 
With purified chromosomal DNA from each of the 9 
Serotypes of S. hyodysenteriae as template, PCR assay 
resulted in 1.55 kb products (FIG. 3). The specificity of the 
1.55 kb products for S. hyodysenteriae was confirmed based 
on production of a restriction endonuclease pattern of the 
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PCR products identical to the predicted restriction map 
analysis of pRED3C6 (data not shown) and positive hybrid 
ization signal with the S. hyodysenteriae-specific internal 
oligonucleotide probe (FIG. 3). The specificity of the reac 
tion for S. hyodysenteriae was further confirmed by the 
absence of products and hybridization signal, respectively 
after gel electrophoresis and Southern blot hybridization 
with internal S. hyodysenteriae-specific oligonucleotide 
probe of PCR amplified chromosomal DNA obtained from 
other cultivable reference isolates of the order 
Spirochaetales, including S. innocenS isolates B256 and 
4/71, other genotypic groups of WBHIS distinct from S. 
innocenS, as well as enteric bacteria including Escherichia 
coli, Salmonella spp., Campylobacter spp., and Bacteroides 
vulgatus. 
EXAMPLE V 
PCR Detection of S. hyodysenteriae from 
Diagnostic Samples 
Samples from uninfected and infected Swine were evalu 
ated by the PCR method for diagnosis of the presence of S. 
hyOdysenteriae. 
1. PCR detection of S. hyodysenteriae in porcine feces 
The sensitivity of the PCR detection of S. hyodysenteriae 
in porcine feces was determined by two Separate methods. In 
a first method, 10-fold serial dilutions of spirochete broth 
cultures were added to constant Volumes of undiluted nor 
mal porcine feces in two Separate experiments. The Sensi 
tivity of the PCR assay was estimated based on the numbers 
of Spirochete cells in the original culture as determined by a 
Petroff-Houser cell counting chamber. Briefly, sterile tubes 
containing 0.1 g of normal feces were inoculated with 1 ml 
containing either sterile PBS (negative control) or serial 
ten-fold dilutions of S. hyodysenteriae isolate B204 cells in 
sterile PBS, from 10 to 10° and vortexed for 5 minutes. 
The samples were allowed to stand for 10 minutes, then the 
Supernatant (approximately 0.9 ml) was drawn off and 
processed for total DNA extraction as described by the 
manufacturer (Nucleon DNA extraction kit, Scotlab, 
Shelton, Conn.) except that the samples were heated at 100 
C. for 15 min prior to the cell lysis step and 5M sodium 
perchlorate deproteinization was replaced by 100 ug of 
proteinase Kper ml. Total DNA from each tube was used for 
PCR amplification followed by agarose gel electrophoresis 
and Southern blot analysis using the S. hyodysenteriae 
Specific oligonucleotide probe. 
In a Second method, feces collected from two untreated 
Swine at the onset of an infection caused by S. hyodysente 
riae were serially diluted ten-fold (10 to 10') in 2 ml 
volumes of sterile PBS. One-ml fractions from each dilution 
then were processed for determination of the total numbers 
of viable S. hyodysenteriae by a plate counting method, and 
detection of S. hyodysenteriae-specific products by the PCR 
assay, respectively. For the plate counting method, a total of 
10 drops of 10 ul each were placed onto freshly made BJ 
Selective medium, and the number of colony forming units 
(CFU) per 0.1 ml was determined after incubation at 42 C. 
in the Gas Pak Anaerobic System (BBL) for 9 days. One ml 
fractions from each ten-fold dilution were processed for total 
DNA extraction, and PCR detection of S. hyodysenteriae, as 
described above. The specificity of the PCR assay for 
detection of S. hyodysenteriae in diagnostic Specimens was 
compared with conventional bacteriological culture on BJ 
medium incubated anaerobically at 42 C. for 10 days. 
Porcine feces (n=3), porcine rectal Swabs (n=2), and porcine 
colonic mucosal Scrapings (n=4) obtained from six different 
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premises where clinical Signs of an infection caused by S. 
hyOdysenteriae were reported by the referring veterinarians 
(Duhamel et al., J. Vet. Diagn. Invest., 4:285-292 (1992)), 
were processed for PCR assays and cultures. For PCR 
assays, total DNA was extracted from 100 ul of Supernatants 
from either dysenteric porcine feces or porcine colonic 
mucosal Scrapings, as described above. Rectal Swabs were 
mixed with 1 ml of sterile PBS for 2 minutes, and the total 
DNA was extracted from the Supernatants. 
Negative controls were included in all PCR assays for 
detection of S. hyodysenteriae in porcine feces. In the Spiked 
feces experiments, unspiked feces and feces Spiked with 
10° dilution of broth culture (100-fold dilution beyond the 
numbers of spirochetes estimated by the Petroff-Houser cell 
counting chamber) were used as negative controls. In the 
experiments using fecal Samples from Swine at the onset of 
an infection caused by S. hyodysenteriae, dilutions beyond 
10' were considered as negative controls (according to 
Kunkle et al., J. Clin. Microbiol., 26:2357–2360 (1988), 
dysenteric feces contain between 10° and 10' CFU/g). In 
the experiments testing diagnostic Specimens, the fecal 
sample containing a WBHIS was used as the negative 
control. 
The sensitivity of the PCR assay for detection of S. 
hyOdysenteriae in Serial ten-fold dilutions of Spirochete 
broth cultures added to normal porcine feces was 1 organism 
per 0.1 g of feces in the first experiment (data not shown), 
and 10 organisms per 0.1 g of feces in the Second experiment 
(FIG.3). The number of spirochetes in dysenteric feces from 
2 untreated Swine were comparable to those reported pre 
viously for the BJ selective culture medium; 1x10 and 
2x10 CFU/0.1 ml, respectively. Kunkle et al., J. Clin. 
Microbiol., 26:2357–2360 (1988). Presence of S. 
hyOdysenteriae-specific products at dilutions up to 10-9 in 
both fecal specimens by PCR assay indicated a 1,000 fold 
increase in Sensitivity compared with conventional culture. 
The 10-1 to 10-12 dilutions yielded negative results by both 
methods. 
Examination of porcine feces, porcine rectal Swabs, and 
porcine colonic mucosal Scrapings obtained from nine Swine 
on six different premises by PCR assays yielded 1.55-kb 
products in all Samples where S. hyodysenteriae was iden 
tified by conventional bacteriological culture method, as 
shown in Table III below. The one sample which was 
negative by PCR assay yielded WBHIS by culture. Table III 
shows a comparison of conventional bacteriological culture 
method on Selective BJagar medium and polymerase chain 
reaction (PCR) assay for detection of Serpulina hyodysen 
teriae in diagnostic Specimens. 
TABLE III 
Sample Result 
Premises Number Type Culture PCR 
A. 1. Feces S. hyodysenteriae -- 
2 RSir S. hyodysenteriae -- 
B 1. MS S. hyodysenteriae -- 
C 1. MS S. hyodysenteriae -- 
D 1. MS S. hyodysenteriae -- 
E 2 Feces S. hyodysenteriae -- 
F 1. MS WBHS 
Total: 6 9 
RS = Porcine rectal swab. 
MS = Porcine colonic mucosal scraping. 
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EXAMPLE VI 
Preparation of Monoclonal Antibodies to S. 
hyOdysenteriae Antigens 
Monoclonal antibodies were raised against cell-free 
Supernatant antigens from S. hyodysenteriae produced by a 
previously described method (Dupont et al., in press) 
according to Standard methods (Hugo et al., J. Clin. 
Microbiol., 25:26-30 (1987)). Polyclonal antibodies were 
raised against two different Synthetic peptides Selected from 
the predicted amino acid Sequence of the 2.3 kb insert of 
clone pRED3C6. 
1. Monoclonal antibody production 
Eight- to ten-week old BALB/c mice were immunized 
intraperitoneally with 100 lug of cell-free Supernatant anti 
gens from S. hyodysenteriae, isolate B204, concentrated 10 
times using a YM5 Diaflow ultrafilter (Amicon, Beverly, 
Mass.) and mixed with equal volumes of Freund's complete 
adjuvant. Dupont et al., Vet. Microbiol., in press (VETMIC 
723). Identical booster injections containing 50 lug of cell 
free Supernatant antigens in Freund's incomplete adjuvant 
were given 14, 28, and 42 days later. Four days after the 
booster injection, Spleen cells were harvested and fused with 
SP 2/0 cells using 50% polyethylene glycol. Hybridomas 
producing antibodies that reacted with cell-free Supernatant 
antigens from S. hyodysenteriae, isolate B204, by ELISA 
were cloned by limiting dilution and stabilized before injec 
tion into mice for asciteS production. Hugo et al., J. Clin. 
Microbiol., 25:26-30 (1987). Monoclonal antibodies 467, 
F11, 1D8/E11, 3E1D/F1, 6C1D/F8 and 10G6/G10 were 
identified and are available from Dr. Duhamel, University of 
Nebraska, Lincoln, Nebr. Hybridoma 10G6/G10 producing 
an IgM monoclonal antibody that reacted with cell-free 
Supernatant antigens of S. hyodysenteriae by ELISA was 
cloned by limiting dilution and stabilized before injection 
into mice for asciteS production (Hugo et al., cited Supra) 
and is available from Dr. Duhamel, University of Nebraska, 
Lincoln, Nebr. 
2. Polyclonal antibodies to synthetic peptides 
Information on the predicted amino acid Sequence 
encoded by the 2.3 kb fragment of clone pRED3C6 provides 
a basis for identification of antigenic domains. Using Hopp 
Woods hydrophobicity plots as an indicator of surface 
orientation and potential antigenicity, two peptides were 
Synthesized and used for production of hyperimmune Sera in 
guinea pigs. Hopp et al., Mol. Immunol., 20:483 (1983). 
Polyclonal antibodies were produced in adult Hartley 
Albino guinea pigs against Synthetic peptides A 
(DPAKASRPFD) and B (IPLFEALKPKT) derived from the 
predicted amino acid sequence of nucleotides 500-529 
(peptide A) and 2093–2126 (peptide B) of the 2.3 kb 
fragment of clone pRED3C6. The initial injection consisted 
of 50 tug of each peptide diluted in 100 ul of sterile water and 
mixed with 100 ul of Freund's complete adjuvant adminis 
tered Subcutaneously. Booster injections containing 100 lug 
of each peptide in 100 ul of sterile water mixed with equal 
Volumes of Freund's incomplete adjuvant were given 14 and 
28 days after the initial injection. Final bleeding was com 
pleted 7 days after the last booster injection. 
EXAMPLE VII 
Identification of the Site of S. hyodysenteriae 
Persistence in Carrier Swine 
A PCR test may be used for Screening replacement Stock 
and during herd elimination programs by analyzing fecal 
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Shedding patterns by Subclinically-infected Swine including 
those on medication as described below. 
1. Define the pattern and identify the site of S. hyodysente 
riae persistence in carrier Swine 
About of 20 specific pathogen-free (SPF) swine will be 
inoculated with S. hyodysenteriae, isolate B204, as previ 
ously described. Elder et al., cited Supra. Each Swine will be 
monitored daily for clinical Signs of an infection caused by 
S. hyodysenteriae (usually within 14 days post-inoculation). 
At least about 30 percent of the Swine most likely will die 
or need to be euthanatized because of Severe clinical Signs. 
The remaining naturally-recovered Swine will be randomly 
allocated to two experimental groupS and housed in Separate 
isolation rooms of the Pig Research Facility (ARF) of the 
Department of Veterinary and Biomedical Sciences. 
The pattern of S. hyodysenteriae Shedding in naturally 
recovered Swine (continuous versus sporadic) will be 
assessed using the PCR assay described in Example V, and 
bacterial culture of fecal Specimens collected every other 
day for 30 days from the day of cessation of bloody diarrhea 
(usually 14 to 21 days after the onset of clinical signs). At 
the end of 30 days, the effect of stress on fecal shedding of 
the spirochetes will be determined. Swine from one experi 
mental group will be taken for a 40-mile truck-ride, placed 
into a disinfected room of the ARF, and the pattern of S. 
hyodysenteriae fecal shedding will be monitored for an 
additional 7 days. 
At the end of the observation period, the Swine in each 
group will be euthanatized and the distribution of S. hyod 
ySenteriae in 15 predetermined sites along the wall of the 
distal ileum, cecum, spiral colon, descending colon, and 
rectum of each Swine will be determined by PCR and 
culture. Duhamel et al., J. Vet. Diag. Invest., 4:285 (1992) 
and Elder et al., cited Supra. DNA extracted from fecal 
Samples (live Swine) and mucosal Scrapings (necropsy 
Specimens) obtained from each Swine will be Subjected to 
PCR amplification followed by agarose gel electrophoresis 
and Southern blot analysis using the S. hyodysenteriae 
Specific oligonucleotide probe, as described in Examples IV 
and V. Results of PCR assay will be compared with con 
ventional bacterial anaerobic culture and will provide an 
indication of the site of S. hyodysenteriae levels in feces and 
tissueS of the Swine over time post-infection. 
2. Analysis of the pattern of S. hyodysenteriae Shedding in 
feces of medicated Swine 
A total of 30 SPF Swine will be infected with S. 
hyOdysenteriae, isolate B204. At the onset of clinical Signs, 
Swine will be randomly allocated to five experimental 
groups of 5 Swine each and medicated with the following 
antimicrobials: Group 1. Carbadox: 50 g/t in feed continu 
ous; Group 2. Tiamulin: 3.5 mg/lb/day in water for 5 days; 
Group 3.35 g/t in feed continuous; Group 4. Lincomycin: 3.8 
mg/lb/day in water for 6 days; Group 5. 100 g/t in feed 
continuous. The pattern of S. hyodysenteriae fecal Shedding 
will be monitored using PCR and bacterial culture every 
other day for 3 weeks after the initiation of medication. At 
the end of the observation period, the Swine will be eutha 
natized and the presence of S. hyodysenteriae in the intes 
tinal tract of each Swine will be determined by PCR and 
culture. Results will show the efficacy of the treatment 
regimens to decrease infection with S. hyodysenteriae even 
to very low levels of invention that can be detected by PCR 
methods. 
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GAT TT G GCA AAT ATT T CA. TAT AAA ATA CTA AAA 
A s p Le ul Al 
TAGA GAA GT T 
G C C C C C T G CT 
C G GAACTTTC 
TAA TATA C CA 
T G CT GAATTC 
TAATT C T GAA 
AAT AT TTACA 
ATT CAATTT 
a As in 
48 5 
I e S e 
TAC GA C C CTA 
C CTA AAA GA G 
CT CA CAT TAG 
TTA TTT GAA G 
GT TAATGAT G 
AG TAT AGAAA 
G G CAATCG TT 
( 2) INFORMATION FOR SEQ ID NO:2: 
r Ty r Lys 
AA CAAAAAGA 
A G GTA A G CAT 
TT G T AAT T G G 
CTTT AAA GCC 
CA GT AAT TAC 
CA CTA A GAA G 
CTTTT AATAA 
( i) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 497 amino acids 
( x 
Me t Wa W a 
1. 
G 1 y P h e As 
Lys A a Se 
3 
A rig Ty r Le 
5 O 
As n Le u As 
5 
Lys Ser Me 
I e S e r A 
Le u Ph e G 
1 1 
Le u I e As 
13 O 
Thr Cy s Ph 
I e Phi e Ph 
I e Lys Se 
1 9 
A la Lys Le 
2 1 
Le u Ty r S e 
2 25 
A s p As in Ty 
( 
( 
B) TYPE: amino acid 
D) TOPOLOGY: linear 
i i ) MOLECULETYPE: protein 
G 1 y G 1 y Se 
5 
As in A a A. r 
2 O 
A rig Pro Ph 
I e Lys As 
A rig V a l As 
As n I l e As 
8 5 
A a G u. As 
1 O O 
Thr G 1 y G 1 
S e r Le u As 
G 1 y Le u Al 
1 5 
Lys A 1 a Hi 
1 65 
Le u Ty r A r 
18 O 
I e Phi e P r 
I e A s p Ty 
L y s A rig Gl 
2 3 
I le G 1 y Al 
2 4 5 
i ) SEQUENCE DESCRIPTION: SEQ ID NO:2: 
r G I u. A 1 a 
g A la L. eu 
e A s p Lys 
4 O 
in G 1 y Ty r 
5 5 
in Lys As p 
O 
p I l e A s in 
n I I e G 1 u 
y As in Arg 
1 2 O 
in L y S L e u 
1 35 
a Ser Lys 
O 
s G 1 u Thr 
g Th r A rig 
o A s p G 1 u 
2 O O 
r As in G u 
2 15 
u G 1 in G 1 y 
O 
a A a Wa 
I e 
4 9 O 
Le u L y s 
ATTAGAATTC 
ATTT G CT AGA 
TAT G CTTTT A 
TAAAACA GAT 
AACTATA GAA 
TT ATTTTT CA 
TATA AGATT C 
Th r I e A s in 
1 O 
Ser Thr Arg 
25 
G l y Arg As p 
A s p V a l L y s 
Thr Ty r S e r 
7 5 
Ty r Le u G 1 y 
9 O 
A rig L y s S e r 
1 O 5 
Pro Le u G u 
A s p V a 1 Le u 
I l e A s in A sp 
1 5 5 
G 1 u T y r I 1 e 
18 5 
I le Le u As p 
Ly is I l e A s in 
Me t Le u A a 
23 5 
Le u A a Wa 
25 O 
38 
GGA TAT AAA TTT GCC 
G 1 y Ty r Ly 
49 
TAC GCTA AAA 
AGAT GGTTTA 
TATAAAAAAG 
GT TATA GT AA 
C T C GAAAA TT 
TT G T A CAAAA 
C CAG TAG GT C 
S 
5 
P r o Le u Thr 
As in A s p As p 
3 O 
G l y Le u A 1 a 
4 5 
I le Ty r I 1 e 
6 O 
As in Phi e A s in 
S e r G 1 u G u 
I e V a Le u 
1 1 O 
G 1 y I le G 1 in 
1 2 5 
A rig I l e A 1 a 
1 4 O 
As in A s p As in 
Cy s Ph e A 1 a 
G 1 y Lys Le u 
1 9 O 
As in T r p G 1 y 
2 O 5 
I l e A s in Arg 
22 O 
I e V a A a 
As in A a A 1 a 
Ph e A 1 a 
GAGA G G T AAA 
T G T TTT TATA 
GATT CTTTAA 
AAA TT AATAA 
CAAAT TATAC 
AT AGAAAA TT 
A GA GAAT AG G 
I e A a 
1 5 
Pro A. a 
I e A a 
Thr G 1 y 
I e Le u 
8 O 
A s p A 1 a 
9 5 
A s p S e r 
Lys A 1 a 
I l e A sp 
V a 1 Ty r 
1 6 O 
L y s As p 
1 7 5 
Ph e I e 
Ty r Lys 
As n S e r 
G 1 y Ser 
24 O 
Ty r A rig 
25 5 
39 
Le u G 1 y V a 1 G 1 y Ty r I 1 e Arg 
2 6 O 
2 7 5 
G l y V a 1 G 1 y G 1 u G 1 u As n G 1 n 
29 O 2 9 5 
I le G 1 y Arg A s p L. eu Se r Thr 
G n I e A s m I e P r o Thr Wa 
3 4 O 
Ph e G u S e r Th r Le u As in G u 
4 2 O 
Me t G 1 y A s p V a 1 Ph e A a G 1 y 
43 5 
Le u As n I le Le u A s p A l a Sle r 
4 5 O 4 55 
48 5 
A 1 a 
( 2) INFORMATION FOR SEQ ID NO:3: 
( i) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 22 base pairs 
(B) TYPE: nucleic acid 
(C)STRANDEDNESS: single 
(D) TOPOLOGY: linear 
( i i ) MOLECULETYPE: DNA (genomic) 
( xi ) SEQUENCE DESCRIPTION: SEQ ID NO:3: 
G G T ACA G G C G GAA ACA GA C C TT 
( 2) INFORMATION FOR SEQ ID NO:4: 
( i) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 20 base pairs 
(B) TYPE: nucleic acid 
(C)STRANDEDNESS: single 
(D) TOPOLOGY: linear 
( i i ) MOLECULETYPE: DNA (genomic) 
( xi ) SEQUENCE DESCRIPTION: SEQ ID NO:4: 
T C CTATT C T C T G A C C T ACT G 
( 2) INFORMATION FOR SEQ ID NO:5: 
3 6 
P r 
Ph 
4 4 
O 
l 
5,869,630 
-continued 
Ty r V a 1 
2 65 
S e r Me t 
Phi e Phe 
A s p A 1 a 
I e Phe 
3 3 O 
A s p A 1 a 
3 4 5 
As in As in 
Thr G 1 m. 
Le u I e 
Wa S e r 
4 
A rig G 1 u 
4 25 
I le G 1 y 
Le u A 1 a 
P he G 1 y 
Lys I le 
4 9 O 
P r 
Th 
S e 
A 
Le 
4 7 
Le 
O 
s 
s 
Gl 
3 O 
I 
Ph 
38 
A r 
Le 
Me 
Le 
l 
l 
O 
e 
e 
G 1 y 
As in 
I e 
Th r 
Le u 
I e 
G u 
Me t 
G 1 y 
4 4 5 
I e 
G 1 y 
I 
2 7 
W a 
Gl 
I 
I 
I 
Gl 
I 
S 
3 3 5 
Th r 
G u 
Th r 
G u 
4 15 
A 1 a 
A rig 
G in 
G u 
G 1 y 
3 2 O 
Me t 
Wa 
G 1 y 
2 2 
2 O 
5,869,630 
41 42 
-continued 
( i) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 28 base pairs 
(B) TYPE: nucleic acid 
(C)STRANDEDNESS: single 
(D) TOPOLOGY: linear 
( i i ) MOLECULETYPE: DNA (genomic) 
( xi ) SEQUENCE DESCRIPTION: SEQ ID NO:5: 
TAGGG G C T G C T G TT CTA G CT G T AAA T G C 
What is claimed is: 
1. An isolated HindIII DNA fragment of about 2.3 kb 
derived from chromosomal DNA of S. hyodysenteriae B204 
comprising the nucleotide sequence of SEQ ID NO:1. 
2. An oligonucleotide probe that Specifically hybridizes 
under Stringent conditions to a target DNA sequence of S. 
hyOdysenteriae, wherein the target Sequence is about a 2.3 
kb HindIII partial digest restriction fragment of S. hyodys 
enteriae B204 which target DNA sequence comprises SEQ 
ID NO:1 and wherein the probe does not hybridize to at least 
one other microorganism. 
3. The oligonucleotide probe according to claim 2, labeled 
with a detectable moiety Selected from the group consisting 
of a biotin labeled nucleotide, radiolabeled nucleotide and a 
fluorescent tagged nucleotide. 
4. The oligonucleotide probe according to claim 2, 
wherein the probe is hybridizable to DNA amplification 
products of primers that Specifically hybridize under Strin 
gent conditions to the about 2.3 kb HindIII partial digest 
restriction fragment of S. hyodysenteriae B204 which 
restriction fragment comprises SEQ ID NO:1 and which 
primers do not hybridize to at least one other microorgan 
S. 
5. The oligonucleotide probe according to claim 2, 
wherein the probe is about 20 to 2300 nucleotides long. 
6. A recombinant DNA expression vector comprising a 
2.3 kb HindIII partial digest restriction fragment of S. 
hyodysenteriae B204 which restriction fragment comprises 
SEQ ID NO:1 operably linked to transcriptional and trans 
lational control regions of the expression vector. 
7. An expression vector according to claim 6 having the 
characteristics of a plasmid pRED3C6, ATCC No. 75826. 
8. A transformed cell carrying a recombinant expression 
vector of claim 6. 
9. An oligonucleotide primer for amplifying a target 
Sequence of S. hyodysenteriae, wherein the primer Specifi 
cally hybridizes under Stringent conditions to a target 
Sequence, wherein the target Sequence is a 2.3 kb HindIII 
partial digest restriction fragment of S. hyodysenteriae B204 
which restriction fragment comprises SEQ ID NO: 1 and 
which primer does not hybridize to at least one other 
microorganism. 
15 
25 
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10. The oligonucleotide primer according to claim 9, 
wherein the oligonucleotide has a DNA sequence compris 
ing positive Sense 
5'-GGTACAGGCGGAAACAGACCTT (SEQ ID NO:3), 
or negative Sense 
5-TCCTATTCTCTGACCTACTG (SEQ ID NO:4), or 
complements thereof. 
11. A kit for use in the detection of S. hyodysenteriae in 
a biological Sample, comprising: 
(a) a first reagent comprising at least one oligonucleotide 
primer that specifically hybridizes under Stringent con 
ditions to a target Sequence of a 2.3 kb HindIII partial 
digest restriction fragment of S. hyodysenteriae B204 
which restriction fragment comprises SEQ ID NO: 1 
and which primers do not hybridize to at least one other 
microorganism. 
12. A kit according to claim 11, further comprising in 
combination: a Second reagent comprising an oligonucle 
otide probe which Specifically hybridizes under Stringent 
conditions to either a 2.3 kb HindIII restriction fragment 
comprising SEQ ID NO: 1 or to an amplified product 
produced using a primer of claim 9 and which probe does 
not hybridize to at least one other microorganism; and the 
reagents packaged within containing means. 
13. The kit according to claim 11, wherein the containing 
means are Selected from the group consisting of a Vial, jar, 
tubes and multiwell plate. 
14. A kit according to claim 11, further comprising 
reagents for extracting nucleic acids from a biological 
Sample. 
15. The kit according to claim 11, wherein the oligonucle 
otide primer has a DNA sequence comprising positive Sense 
5'-GGTACAGGCGGAAACAGACCTT (SEQ ID NO:3), 
or negative Sense 
5'-TCCTATTCTCTGACCTACTG (SEQ ID NO:4), 
complements thereof, or mixtures thereof. 
16. A kit according to claim 11, further comprising 
reagents for conducting the polymerase chain reaction. 
17. An isolated nucleic acid consisting of SEQ ID NO: 1. 
k k k k k 
